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Abstract
Hepatitis C (HCV) infection is the most common bloodborne illness in the United States and the
prevalence is highest in those born between 1945 and 1965. Most of those with HCV infection in this
cohort have been infected for decades and some are now experiencing the long-term consequences
of HCV infection, including cirrhosis and hepatocellular carcinoma. At the same time, this cohort is
just reaching the age of eligibility for Medicare. The introduction of new treatment protocols includ-
ing direct-acting antivirals for HCV infection has resulted in better outcomes for those undergoing
treatment with many achieving a cure of their HCV infection. Despite an awareness of the potential
burden of disease from HCV infection in this cohort, there is still a lack of information regarding
hepatocellular carcinoma outcomes in persons with HCV and the impact of treatment for HCV out-
comes and transmission. Using the Surveillance, Epidemiology, and End Results data linked to
Medicare claims, this research describes (1) changes in risk factors for hepatocellular carcinoma,
including HCV infection, over time and (2) differences in outcomes of persons with hepatocellular
carcinoma by HCV infection status in the Medicare population. In addition, a state transition model
with a transmission equation was used to compare the impact of treatment on mortality and HCV
transmission using direct-acting antivirals to treat persons born between 1945 and 1965 in two risk
populations, persons who inject drugs and persons who don’t inject drugs. Overall, this research
adds to our understanding of the consequences of HCV-infection-related hepatocellular carcinoma
and the impact of treatment in the population with the highest prevalence of HCV infection.
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Chapter 1
Introduction and background
1.1 Statement of purpose
The purpose of this dissertation is to contribute to the body of knowledge on the outcomes of hepatitis
C infection and hepatitis C treatment with a particular focus on HCC. While there are a number of
areas where more information is needed, the focus of this research is to address three questions:
1. Among Medicare beneficiaries diagnosed with HCC, are there differences in risk factors over
time, and doHCC cases with risk factors have differences in cancer characteristics at diagnosis
and different prognosis after HCC diagnosis?
2. Among Medicare beneficiaries diagnosed with HCC, is the prognosis different for those who
have hepatitis C infection and those who do not have hepatitis C infection after HCC diagno-
sis?
3. What is the impact of new treatments for hepatitis C infection on morbidity and mortality from
hepatitis C infection in the United States?
1.2 Background and significance
1.2.1 Hepatitis C disease
Hepatitis C is a viral infection that primarily affects the liver. Hepatitis C virus (HCV) infection is
transmitted through blood-to-blood contact such as blood transfusions before screening of the blood
supply in 1990, medical procedures with unsterile equipment, sharing of injection-drug-use equip-
ment, and contaminated supplies for tattooing and body piercing. An estimate based on National
1
Health and Nutrition Examination Survey (NHANES) data is that there are 2.7million to 3.9million
(1.0–1.5%) persons living with chronic HCV infection in the United States, making it the most com-
mon bloodborne infection.1 The Centers for Disease Control and Prevention (CDC) estimates that
there were approximately 16 500 new HCV infections in 2011.2 Chronic HCV infection develops in
75–85% of those initially infected with HCV.3 Chronic HCV infection can lead to cirrhosis, hepa-
tocellular carcinoma, and death. A recent review of studies estimating the costs of HCV infection in
the United States found that estimates of the direct costs of HCV infection ranged from $694million
to $1660million and indirect costs ranged from $51million to $3370million, but all of the studies
included in the review were based on publications from the 1990s, and estimates of the costs of
sequelae of HCV infection may not be correct 20 years later.4
Data on chronic HCV infection in the United States come from a number of sources. Prevalence
estimates used by CDC are largely based on the results of NHANES. Not all states conduct follow-
up on cases of chronic HCV infection. For 2010, the most recent year for which data are available,
only 10 states had reported chronic HCV data to CDC and agreed to have it included in the annual
data summary.2 The case definition for HCV includes both current chronic infections and resolved
infections, so these data include persons with no evidence of current infection.
A study published in 2008 found that deaths in the United States from HCV infection had in-
creased from 2798 in 1995 to 7426 in 2004.5 The prevalence of HCV infection varies by birth year
in the United States with the highest rates of reported infection occurring in those born in the 1940s,
1950s, and 1960s.6 In 2012, CDC recommended screening for all persons born between 1945 and
1965.6 This is the first group for which universal screening for HCV is recommended. Data from
NHANES was used to estimate the number of cases of chronic HCV in this cohort at 2.06million.6
This represents 54–77% of the total estimated infections in the United States, while this cohort
makes up only 11% of the U.S. population.1,6,7 This cohort was exposed to hepatitis C primarily
through injection drug use and blood transfusions before the blood supply was screened for HCV.
Persons born in 1945–1948 are currently 65 years of age or older and are now eligible for Medicare,
and over the next 16 years these HCV-infected persons will continue to age into Medicare. This has
created concern about what costs of caring for this group of people will be as they have been living
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with HCV for decades, many undiagnosed and not receiving appropriate care.4 While persons born
between 1945 and 1965 represent a large proportion of cases in the United States, HCV is not only
a disease of those over 49. Over the last five to ten years, viral hepatitis surveillance systems in a
number of states have detected an increase in HCV in younger adults. New York and Massachusetts
were the first to detect clusters of cases and overall increases in cases in young adults.8,9 This in-
crease has resulted in increasing concern about previous assumptions regarding the future costs of
HCV infection in the United States.4
1.2.2 Hepatitis C prevention and treatment
There is currently no vaccine available for HCV, and prevention consists of encouraging use of safer
injection-drug-use practices or discontinuation of injection drug use. Continued use of sterile medi-
cal equipment, testing of the blood and organ supply, and universal precautions are also prevention
strategies. Treatment is available for chronic HCV infection, and until 2011, the recommendation of
the American Association for the Study of Liver Disease (AASLD) was combination treatment with
pegylated interferon alfa and ribavirin.3 This combination takes over 24 to 48 weeks to complete
and has serious side effects such as severe fatigue, flu-like symptoms, anxiety, depression, and hair
loss. The goal of treatment is to achieve clearance of the virus demonstrated by two undetectable
HCV ribonucleic acid tests, one immediately following treatment, and a second six months after the
end of treatment. If both are negative, the outcome of treatment is called a sustained virologic re-
sponse (SVR). In its guidelines, the AASLD recommends that certain patients, primarily those with
evidence of liver damage, receive treatment to decrease the likelihood of disease progression and
outcomes like severe liver disease, hepatocellular carcinoma, and death.3,10 The high costs of treat-
ment, both monetary and personal, and moderate success rates lead to caution when recommending
treatment universally.
Between 2011 and 2013, the U.S. Food and Drug Administration approved four new direct-
acting antivirals (DAAs) for the treatment of HCV infection. In clinical trials, these drugs have
shown increased rates of SVR when added to the previously recommended HCV treatments.11–23
There are six genotypes of HCV infections, designated with the numbers 1 through 6. Genotype 1
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is the most common in the United States at an estimated 74–80% of cases.24–26 The rate of SVR
varies by genotype, with genotype 1 having the lowest rates of SVR with treatment protocols with-
out DAAs.10 Some new treatment protocols eliminate interferon completely, eliminating some side
effects that have kept some from treatment until this point. DAAs are currently recommended for
all HCV genotypes.10
The goal of treatment guidelines such as those created by the AASLD is to prevent serious long-
term consequences of HCV infection. In general, public health agencies such as CDC and state
health departments have focused their limited HCV-related resources on determining the burden
of disease in the United States from HCV infection and preventing new HCV infections through
education and provision of access to clean injection-drug equipment. Public health interventions
up to this point have focused on reducing the risk of exposures occurring by educating people to
avoid exposure and reducing the likelihood of transmission when exposures occur. Referral to care
and financial assistance for treatments for HCV infection have been limited mostly to those who are
co-infected with HIV. The goals of HCV treatment are not out of line with the public health goals
for reducing the burden of disease from HCV infection and prevention of continued transmission of
HCV. By achieving SVR in an individual patient, the provider has assisted in preventing long-term
consequences of HCV infection for that person and potentially preventing transmission to others by
reducing the reservoir of HCV in the community.
1.2.3 Liver cancer and hepatitis C
Liver cancer incidence is increasing in the United States, with an increase from 5.84 per 100 000 in
1999 to 8.35 per 100 000 in 2011.27 Hepatocellular carcinoma (HCC), the most common liver cancer,
is one of the potential long-term consequences of HCV infection. HCC usually occurs as a result of
cirrhosis of the liver, which can be caused by HCV infection as well as hepatitis B (HBV), alcohol
abuse, autoimmune disorders, liver inflammation, and high iron levels.28 Certain persons with HCV
infection aremore likely to get HCC, includingmen, older persons, personswho use large amounts of
alcohol, persons with hepatitis B infection, persons with HIV, and those with evidence of cirrhosis.29
Estimates of the prevalence of HCC in those with chronic HCV infection range from 4 to 9% after
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10 to 40 years of infection.30,31 The 5-year relative survival for HCC is 30% for localized HCC,
11% for regional HCC, and 3% for distant spread.27
1.2.4 Literature review
Hepatitis C and hepatocellular carcinoma
The literature on HCV-related HCC is well developed in some areas and limited in others. The
existing studies tend to focus on two areas: progression to HCC in persons with HCV infection, and
outcomes of HCC in persons with HCV infection. The literature on the former is more extensive
than the latter. The literature on the progression of HCV infection to HCC can be further divided
into two separate areas: (1) determinates of progression from HCV infection to HCC and (2) the
effect of treatment on progression from HCV infection to HCC. I will discuss each of these three
areas in detail.
Progression of hepatitis C infection to hepatocellular carcinoma
Reviews by Fattovich, Stroffolini, Zagni, and Donato and Bruno, Savojardo, Almasio, and Mondelli
identified a number of risk factors for progression to HCC in persons with HCV.32,33 Fattovich et
al. found 28 longitudinal studies from various geographic areas that looked at HCC in persons with
HCV.32 These studies were grouped into two categories: those looking at persons with chronic HCV
and those looking at persons with compensated cirrhosis. The cumulative 5-year risk of HCC in per-
sons with HCV was 17% in the United States and 30% in Japan.32 The difference in risk between
geographic areas was not explained by differences in patient characteristics, and the authors recom-
mended further exploration of why the risks were so much higher in Japan. The review identified a
number of risk factors for HCC that were deemed important. These included age at infection, age
at diagnosis, severity of liver disease at diagnosis, gender, alcohol use, co-infection with hepatitis
B, and porphyria cutanea tarda.32 A number of potential factors affecting progression to HCC were
not included as important factors labeled by the authors as controversial, insufficient evidence, or
growing evidence. These included diabetes mellitus, occult hepatitis B infection, HIV infection, iron
overload and smoking.32 As recently as 2011, a review by Bruno et al. contained an almost identical
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list with no major changes in risk factor classifications.33
Ikeda et al. followed a cohort of 183 patients with HCV-related cirrhosis at monthly intervals for
bloodwork and annual imaging.34 They found that 29% hadHCC five years after diagnosis and 54%
had HCC ten years after diagnosis of cirrhosis.34 They also identified elevation of alpha-fetoprotein
greater than 20 ng/mL, gender, and platelet count less than 100 000/mm3 as predictors of HCC.34
A Japanese cohort study examined the relationship between viral load of HCV and HCC incidence
and found the hazard ratio for those with detectable viral load compared to those without detectable
viral load was 35.8, but, for those with a detectable viral load, there was no viral-load-dependent
risk increase.35 Although a Canadian cohort study looked at the impact of immigrant status on HCC
development in HCV-infected persons with advanced fibrosis and found it not to be an independent
risk factor, the study did find an association between type 2 diabetes and HCC in the cohort.36 It
found that immigrants in their cohort had a higher prevalence of type 2 diabetes and were older than
other cases, which resulted in higher incidence of HCC.36
Walter et al. used health department data from an area in Australia to explore risks for HCC in
cases of HCV reported to the health department.29 The cancer diagnoses for cases were gathered
from the cancer registry for the same geographic area. The authors found that being male, having
hepatitis B, having alcoholic liver disease, having cirrhosis, living in an urban area, and having a
higher comorbidity score were all indicators of higher risk of HCC. In addition to the cohort studies
that have looked at HCC incidence, a study from India using a case-control design found many of
the same risks, but also suggested that poor standards of living, HCV genotype 4, and certain host
gene mutations were associated with developing HCC in those with HCV.37
Measuring the impact of therapy on progression from HCV infection to HCC is challenging, as
there can be a long interval between treatment and onset of HCC. Currently published studies that
try to answer this question are largely evaluating older treatment protocols or using other surrogate
endpoints to estimate the impact of treatment on HCC in the future. A review by Shen et al. of
22 studies found that antiviral therapy was associated with decreased HCC incidence at three and
five years post treatment.38 The resulting decrease at five years was 7.8%. A number of different
treatment protocols were examined in separate studies and all showed at least some benefit in some
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patients.38–43 Interferon treatment was shown to reduce the risk of HCC in persons who achieved
SVR.39,41,42 The benefits of interferon in non-responders to therapy have been mixed; one of three
studies showed a significant decrease in risk among non-reponders.42
Outcomes of hepatocellular carcinoma
Only two studies looked at outcomes of persons with HCV and HCC compared to others with HCC
only. Reddy et al. comparedHCC caseswithHCV to thosewith nonalcoholic hepatitis and found that
HCV patients had a shorter overall survival time, but not a significant difference in recurrence-free
survival after curative therapy.44 In contrast, Takuma et al. found that persons with HCV and HCC
had lower rates of recurrence and lower mortality than those with HCC and cirrhosis of an unknown
cause.45 One additional study looked only at patients with HCV and HCC to examine the role of viral
load in determining outcomes of HCC after resection. Shindoh et al. found that patients with low
viral load had better long-term outcomes after resection.46 Other studies have looked at outcomes
for persons with HCC, but not looked at HCV patients specifically. Higher body mass index was
also found to be a predictor of poorer outcomes, including increased recurrence and shorter survival
times.47
Models of hepatitis C outcomes/Impact of treatment on outcomes
The literature on models of the impact of HCV treatment from a public health perspective is limited,
but Volk, Tocco, Saini, and Lok attempted to determine the public health impact, measured as deaths
prevented, of treatment of HCV infection using current treatment protocols (which, at the time, did
not include HCV DAAs).48 That study found that with treatment 14.5% of deaths from liver-related
causes resulting from HCV infection would be prevented.48 Zhang, Mehra, and DiBello also looked
at the impact of HCV treatment on morbidity and mortality for HCV infection.49 The goal of their
model was to examine the impact of the new HCV protease inhibitors on HCV prevalence and
outcomes. Their analysis included outcomes in addition to mortality and included the secondary
impact of cases prevented due to treatment of existing cases. Zhang et al. found that there would be
a reduction in prevalent cases of HCV infection of 19% by 2040 if protease inhibitors were added
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to the treatment protocol starting in 2011.49 The model predicted 5% fewer deaths when using new
treatments between 2011 and 2040 compared to the previous treatment protocol.49
There are a number of models of the impact of HCV treatment on HCV prevalence specifically in
persons who inject drugs.50–55 While conducted in other countries, primarily Australia, Canada, and
the United Kingdom, the results are of interest. Overall treatment of persons who inject drugs was
found to reduce the prevalence of HCV infection, but the impact varied by the prevalence of HCV
in the population.50–55 This was found even when potential reinfection in those treated for HCV
was taken into account.53 Treatment of persons who inject drugs was found to be cost-effective
when the prevalence of HCV infection in persons who inject drugs was less than 60%.53 With the
introduction of DAAs and expected introduction of DAA regimens without interferon, Martin et al.
estimated costs of $3.2million to $5million to halve the prevalence of HCV infection depending on
the prevalence in the geographic area.50
After the introduction of DAAs, Liu et al. conducted a cost-effectiveness analysis for the early
DAAs in persons with genotype 1 HCV infection with mild or advanced fibrosis and Liu, Schwarzin-
ger, Carrat, and Goldhaber-Fiebert conducted a cost-effectiveness analysis of screening for fibrosis
before treatment.56,57 The findings indicated a decrease in HCC risk and an increase in quality-
adjusted life expectancy for both mild and advanced fibrosis. It was also found that protease in-
hibitors are cost effective for treatment of genotype 1 and that screening for fibrosis is not preferred
prior to treatment.
Limitations of the literature: Hepatitis C and hepatocellular carcinoma
There are a number of gaps in the existing literature, some of which will be difficult to address
in the near future. Information on the impact of current treatment protocols on the incidence of
HCC in persons with HCV is not available, and will likely take a number of years to fully describe.
In addition, the outcomes of those with HCC have been described, but the differences in outcomes
between thosewithHCV andHCC compared to others are lacking. Tomake up for these gaps, results
of studies looking at the outcomes of persons with HCC in general have been used in place of specific
HCV-infection-related HCC outcomes. This substitution appears to be based on the progression to
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HCC in persons with HCV infection where the infected person first develops cirrhosis and then
HCC.30,31,58 Since cirrhosis is also the precursor to HCC in persons without HCV infection, the
outcomes of persons with HCV infections are assumed to not differ from the overall outcomes for
persons with HCC.32
Models of hepatitis C outcomes/Impact of treatment on outcomes
Previous modeling studies begin to answer the question of what the public health impact of HCV
treatment might be and what can be done to increase the public health impact of treatment for HCV
infection, but only uses reductions in mortality to measure the impact of HCV treatment.48 Volk did
not attempt to quantify the impact of HCV treatment on other outcomes such as hepatocellular carci-
noma. There are models that incorporate HCV transmission to predict reductions in HCV infection,
morbidity, and mortality, but the authors do not use their model to identify strategies to increase the
impact of HCV treatment beyond the addition of protease inhibitors to treatment protocols.49 Most
of the models looking at HCV treatment as prevention were done using older treatment protocols
with only one looking at interferon-free treatment.50 The Liu, Schwarzinger, Carrat, and Goldhaber-
Fiebert model focused solely on cases of chronic HCV genotype 1 with fibrosis and did not look at
other genotypes or treatment for persons without fibrosis.57 In general, the results of previous mod-
eling studies indicate that treatment of persons who inject drugs is preferred in some populations
with lower prevalence. At this time there is nothing looking at new HCV treatment protocols in a
population of great interest in the United States, persons born between 1945 and 1965, and whether
treating persons who inject drugs in this population would be preferred.
1.2.5 Contribution
Based on gaps in the current literature and building on the research described above, there are a
number of areas where research would contribute a new understanding of HCV outcomes and treat-
ment. I will attempt to improve the understanding of changes in risk factors for HCC over time, the
differences in outcomes from HCC related to HCV versus other causes, and the impact of new HCV
treatments as they pertain to morbidity and mortality from HCV.
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Continuing to build on the available information on the proportion of HCC cases with HCV will
allow for better estimates of the impact of HCV in the United States. Describing differences in the
populations with and without HCV and other HCC risk factors will contribute to our knowledge of
the causes of HCC in the United States and changes in those risks over time. Identifying differences
in outcomes of those who have progressed to HCC by HCV status will add to the knowledge of
health care providers and those researching new treatments for HCC.
The impact of treatment onHCVoutcomes is of interest as personswithHCV are being identified
as a result of new screening guidelines and are aging into Medicare. The approval of DAAs has
changed the treatment protocols for HCV infection and it appears reasonable to expect that these
new drugs will increase the impact of HCV treatment beyond the levels predicted in past models.
By adding new treatments, including genotype-specific disease states, and focusing on a population
currently targeted for treatment in the United States, my model will provide information on the
benefit of treating persons who inject drugs compared to those who are not actively injecting.
1.2.6 Theory and conceptual model
As described in the literature, viral hepatitis is a public health problem currently being faced by
the United States. Strategies for addressing HCV through state and local health departments have
focused on case counting, describing the disease burden, educating the public, educating providers,
and integrating viral hepatitis services into HIV and STD programs. At the same time, research has
expanded to include factors affecting HCV transmission, progression to serious sequelae, therapies
for treating those infected, vaccines to prevent transmission, and more. To better address the public
health problem of HCV infection, steps must be taken to incorporate data from current research into
health department programs as well as to further expand on what is known about HCV.
One possible area for public health intervention for HCV is linkage to care. State health de-
partments have started programs to get newly diagnosed persons with HIV into care and to identify
persons who are no longer in care. Viral hepatitis programs have been unable to undertake this for
a number of reasons including lack of funding for public health programs addressing HCV, no data
of populations infected with chronic HCV, a larger population infected with HCV, lack of availabil-
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Figure 1.1: Conceptual model
Incidence HCV Treatment
Liver cancerOther liver-cancerrisk factors SVR (cured)
Dead: Liver-
related
Dead: Other
causes
Chapter 2 Chapter 4
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ity of funding for HCV-related health care, and difficult treatment regimens with varying success.
Most of these barriers still exist, but with the development of new treatments, increased availability
of data on the burden of disease, and potential for a higher proportion of cases to have health insur-
ance (through Medicare as they age or through new coverage options from the Affordable Care Act),
exploring the best ways to focus linkage to care programs seems to be appropriate.
Figure 1.1 illustrates the conceptual model of the progression of HCV infection. In the model, I
have identified the three relationships that I plan to explore in my thesis:
1. Differences in HCV infection and other risk factors for HCC in Medicare beneficiaries over
time and differences in populations with and without risk factors identified.
2. Differences between Medicare beneficiaries diagnosed with hepatocellular carcinoma who
have HCV infection compared to those who do not have HCV infection.
3. The impact of new treatments for HCV on morbidity and mortality from HCV in the United
States in persons born from 1945 to 1965.
The first question deals with differences in persons with HCC by HCV diagnosis and other risk
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factors over time, while the second deals with differences in persons with HCC depending on HCV
diagnosis. The third question looks at the impact of treatment on outcomes including HCC and mor-
tality. As shown in the conceptual model, the number of persons with HCV depends on the number
of new cases and the number of treatment failures. These numbers are influenced by the likelihood of
exposure to HCV (prevalence of HCV in the population and the individual risk of exposure through
routes such as injection drug use) and the likelihood of treatment success. Treatment has two po-
tential outcomes: SVR and no SVR (detectable viral load remaining at the end of treatment). The
outcome of treatment is influenced by patient characteristics including race. Successful treatment
results in clearance of the virus and a decrease in risk for long-term consequences of HCV infection.
Those with ongoing HCV infection are at risk of a number of consequences of HCV infection includ-
ing liver cancer and cirrhosis. The model has been simplified to show all persons with chronic HCV
infection as “infected” regardless of disease status. Death can occur from HCV-infection-related
causes other than liver cancer (shown in the model as progression from chronic HCV infection to
death: liver-related) or through progression to liver cancer.
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Chapter 2
Risk factors for hepatocellular
carcinoma in Medicare beneficiaries,
2000–2009
Context Liver-cancer incidence and mortality are increasing in the United States and hepatitis C
is a likely contributor to that increase. The increasing age and duration of infection of the
population with hepatitis C infection has the potential to increase the number of Medicare
beneficiaries with hepatocellular carcinoma caused by hepatitis C infection over the next 20
years. Screening recommendations for hepatocellular carcinoma in those with hepatitis C
infection and cirrhosis should lead to earlier diagnosis and better hepatocellular carcinoma
outcomes over time.
Objective To describe changes in the Medicare population with hepatocellular carcinoma, changes
in stage at diagnosis, and changes in outcomes over time
Design Cohort study
Setting SEER-Medicare matched data
Patients Cases of hepatocellular carcinoma reported to SEER.
Main outcome measures Changes over time in risk factors for hepatocellular carcinoma, stage at
diagnosis, and survival duration after hepatocellular carcinoma diagnosis
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2.1 Introduction
In the United States, liver-cancer incidence has increased from 5.0 per 100 000 in 1999 to 7.1 per
100 000 in 2010.59 HCC, the most common liver cancer, is one of the potential long-term conse-
quences of HCV infection. HCC usually occurs as a result of cirrhosis of the liver, which can be
caused by HCV infection as well as HBV infection, alcohol abuse, autoimmune disorders, liver
inflammation, and high iron levels.28 Estimates of the prevalence of HCC in those with chronic
HCV infection range from 4 to 9% after 10 to 40 years of infection.30,31 The highest prevalence of
HCV infection in the United States is in those born in the 1940s, 1950s, and 1960s, and most of
these infections occurred decades ago.6 Two previous studies using the Surveillance, Epidemiology
and End Results (SEER) cancer registry and Medicare-linked database found that the proportion of
HCC cases with HCV infection had increased over the 1990s from 11% to 17% of HCC cases.60,61
Although the cohort with the highest rates of HCV infection is not yet present in the linked SEER-
Medicare data set, HCV prevalence is higher in those born in the late 1930s and early 1940s com-
pared to earlier cohorts.6 As the population with the highest prevalence of HCV infection continues
to reach the age of eligibility for Medicare, HCV-related HCCwill likely continue to increase. Other
risk factors for HCC have been increasing over the same period.60,61 Both previous SEER-Medicare
HCC studies looking at risk factors over time found a decrease in the number of cases without an
identified risk factor for HCC.60,61
Screening for HCC is recommended in some groups at increased risk for HCC. These include
certain persons with HBV infection and those with cirrhosis, including those with cirrhosis and
HCV infection, HBV infection, alpha 1-antitrypsin deficiency, or genetic hemachromatosis.62 The
AASLD recommends screening persons who fall into one of these categories using ultrasound every
six months.62 Screening for HCC has been shown to increase the number of cases detected at an
earlier stage and to improve survival.63–66 Survival in persons with HCC has been shown to be
higher for cancers diagnosed at an earlier stage.65,67–69 With an increasing number of HCC cases
occurring in those with an identified risk for HCC and recommendations for routine screening for
HCC on pace in those with high risk, HCC should be diagnosed at an earlier stage leading to better
outcomes from HCC for those HCC cases. The goal of this study is to examine whether stage at
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diagnosis changes over time for Medicare beneficiaries with HCV or another identified risk factor,
whether survival increases over time, and whether survival is associated with diagnosis at an earlier
stage of HCC treatment.
2.2 Methods
2.2.1 Data
The data used for this analysis were from the SEER registry linked to Medicare claims data. SEER
is a surveillance system made up of a number of population-based tumor registries in states and
metropolitan areas. For cases diagnosed in 2000 and later, SEER registries cover 27% of the U.S.
population.70,71 Data are collected on demographic, clinical, and cause-of-death information for
persons with cancer in these areas. The data are then linked with Medicare claims and distributed
by the National Cancer Institute (Calverton, MD).72 The cohort for this analysis was persons who
were Medicare enrolled and diagnosed with HCC between 2000 and 2009. Medicare claims data
were available through 2010. Louisiana SEER registry data from 2005 were excluded due to data-
collection issues following hurricane Katrina. Rural Georgia SEER registry data were excluded
from the analysis due to the small sample size.
2.2.2 Case classification
HCC cases were defined using International Classification of Disease for Oncology codes 8170–
8172 and 8174–8175 identified from SEER sources. All HCC cases diagnosed at age 66 or older
with current enrollment based on age were included. We limited cases to those who were likely
to have complete claims. That is, they had at least one year of continuous enrollment in Part A
and Part B before the HCC. The cohort was limited to those not enrolled in a health maintenance
organization due to lack of claims data for those in managed care plans. Cases without a diagnosis
date or any Medicare claims prior to diagnosis were excluded. Cases with dates of death or dates of
birth varying by more than three months between the SEER death date andMedicare death date were
excluded. We limited our cohort to those reported through hospitals, radiation treatment centers or
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medical oncology centers, laboratories, physician’s offices, and hospital outpatient units or surgery
centers. We excluded cases whowere diagnosed based on death certificate, autopsy, or nursing home
reporting only.
Risk factors included in this analysis include viral hepatitis (types B and C), genetic conditions,
autoimmune conditions, alcohol abuse, obesity, diabetes, and tobacco use. Risk factors were mea-
sured foe the 12 months before HCC diagnosis. The metabolic and genetic risk factor category was
not included in individual outcome comparisons because less than 1% of cases had a risk of this type
identified. It was included in the count of total number of risk factors. Diagnosis for risk factors
for HCC was based on International Classification of Diseases, Ninth Edition (ICD-9), diagnosis
codes that were identified from at least one hospitalization (MedPar) record or two Outpatient (OP)
or Carrier (NCH) records on separate dates. Risk factors for HCV infection were found using ICD-9
codes as described in Appendix B and for each risk individual cases were classified as having the
risk factor or not having the risk factor. Year of diagnosis was taken from the Patient Entitlement
and Diagnosis Summary File (PEDSF) using date of HCC diagnosis from SEER sources. The cases
were divided into two equal time periods, those diagnosed from 2000 to 2004 and those diagnosed
from 2005 to 2009.
2.2.3 Demographic characteristics
The demographic characteristics of interest for this analysis were sex, race, and age at diagnosis.
Demographic variables were all taken from the Patient Entitlement and Diagnosis Summary File
using items collected from SEER sources.
2.2.4 Tumor characteristics
Cancer stage was determined using SEER historic stage (i.e., localized, regional, distant, and un-
staged). The American Joint Committee on Cancer (AJCC) stage was unavailable for almost half
of the cases but AJCC stage and historic stage were largely consistent. The majority of HCC cases
in the analysis data set were not histologically confirmed. We did not include information in our
analysis about grade as it was unavailable for over 40% of cases.
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2.2.5 Treatment
First course of treatment for HCC included surgical resection, radiation, chemotherapy, and/or liver
transplant. We used SEER variables for surgical resection (sxprif1–sxprif10) and radiation (rad1–
rad10). Surgery was defined as surgery of the primary site using the site-specific codes for liver and
intrahepatic bile ducts.73 Radiation therapy was defined as having received radiation therapy for the
liver cancer instance. Chemotherapy was found in the Medicare Outpatient (OP) and Carrier (NCH)
files during the first six months after diagnosis and was defined as Healthcare Common Procedure
Coding System (HCPCS) codes 96400–96549 and Q0083–Q0085.74 Cases with an ICD-9 code of
V42.7 (liver replaced by transplant) or 996.82 (complications of transplanted liver) in the Medicare
Hospitalization (MedPar) file within three months of diagnosis were considered to have received a
liver transplant as part of cancer treatment.
2.2.6 Analysis
Data were analyzed using SAS 9.3 (SAS Institute, Cary, NC). HCC cases were compared across
two HCC diagnosis periods from 2000 to 2004 and from 2005 to 2009. Risk factors were grouped
into categories (i.e., HBV infection, HCV infection, genetic and autoimmune conditions, obesity,
tobacco use, alcohol abuse, and diabetes) and the proportion of HCC cases with each risk factor
were compared across time periods. Stage at diagnosis was compared between time periods, by
risk group, and by stage at diagnosis over time stratified by risk factor. Tumor characteristics and
demographic characteristics were described within risk groups for the entire time period examined.
Models were adjusted for risk factors and demographic characteristics as indicated. Chi-squared
tests were used. All tests of statistical significance were two-sided and with a p value of <0.05
considered statistically significant. A Kaplan-Meier analysis was used to calculate median survival
with (95%) confidence intervals by risk-factor groups and stage at diagnosis, and log-rank testing
was used to determine statistical significance.
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2.3 Results
2.3.1 Demographic characteristics by risk factor
Cases with identified risks were younger than cases without an identified risk factor. The median
age of those with one or more identified risk factor was 75.0 years and the median age of those with
no risk factor was 76.9 years (p < 0:001). Sex varied by risk factor from the overall proportion
of 67% male and 33% female. The proportion of males was highest among HCC cases with HBV
infection (74% male, p < 0:001), tobacco use (79% male, p < 0:001), and alcohol abuse (85%
male, p < 0:001). The proportion among femaleswas highest amongHCC caseswithHCV infection
(44% female, p < 0:001), obesity (40% female, p = 0:04), and cirrhosis (38% female, p < 0:001).
The distribution of diabetes cases by sex did not vary significantly from the overall distribution
among HCC cases (67% male and 33% female, p = 0:22).
2.3.2 Stage at diagnosis by risk factor
Over the entire period of study, 2000 to 2009, certain identified HCC risk factors were associated
with being diagnosed at an earlier stage of HCC. Having identified HCV infection (p < 0:001),
identified HBV infection (p < 0:001), and cirrhosis (p < 0:001) were associated with diagnosis
at an earlier stage. Having a history of alcohol abuse was associated with diagnosis at a later stage
(p = 0:008). Tobacco use and obesity were not significantly associated with stage at diagnosis.
2.3.3 Risk factors over time
From the first time period, 2000 to 2004, to the second time period, 2005 to 2009, the proportion
of HCC cases with HCV infection increased from 13% to 17% (p < 0:001) and the proportion of
cases with HBV increased from 4% to 5% (p = 0:013) (Table 2.1). The proportion of HCC cases
with diabetes increased from 43% to 49% (p < 0:001), alcohol abuse from 4% to 6% (p < 0:001),
obesity from 2% to 3% (p < 0:001), and tobacco use from 3% to 5% from the first time period
to the second time period. Fewer HCC cases had no risk factor identified in the second time period
with 39% of those diagnosed from 2000 to 2004 with no identified risk factor compared to 31% of
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those diagnosed from 2005 to 2009 (p < 0:001). The proportion of HCC cases with two risk factors
increased from 15% to 19% and proportion with three or more risk factors increased from 7% to
10% from the first time period to the second.
Table 2.1: Case characteristics of hepatocellular carcinoma cases by year of diagnosis
Total 2000–2004 2005–2009
p-value
n % n % n %
HCC cases 9860 4298 5562
By gender 0.979
Male 6574 67 2865 67 3709 67
Female 3286 33 1433 33 1853 33
By race 0.683
White 6863 70 3023 70 3840 69
Black 774 8 321 7 453 8
Other 504 5 217 5 287 5
Asian 1206 12 520 12 686 12
Hispanic 420 4 179 4 241 4
American Indian 74 1 28 1 46 1
Unknown† 19 0 NA NA
By age at diagnosis 0.103
65–69 1925 20 819 19 1106 20
70–74 2680 27 1215 28 1465 26
75–79 2525 26 1116 26 1409 25
80–85 1762 18 750 17 1012 18
85+ 968 10 398 9 570 10
By HCV status <0.001
HCV case 1505 15 564 13 941 17
Not HCV case 8355 85 3734 87 4621 83
By HBV status 0.013
HBV case 495 5 189 4 306 5
Not HBV case 9365 95 4109 96 5256 95
By risk-factor group
Diabetes 4515 46 1828 43 2687 48 <0.001
Cirrhosis 2324 24 915 21 1409 25 <0.001
Hepatitis C 1505 15 564 13 941 17 <0.001
Hepatitis B 495 5 189 4 306 5 0.013
Alcohol abuse 478 5 172 4 306 5 <0.001
Tobacco use 424 4 135 3 289 5 <0.001
Obesity 211 2 58 1 153 3 <0.001
Metabolic or genetic 14 0 NA NA 0.552
factor†
Number of risks identified <0.001
One risk 3948 40 1719 40 2229 40
Two risks 1707 17 629 15 1078 19
Three risks or more 815 8 281 7 534 10
No risk identified 3390 34 1669 39 1721 31
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Table 2.1, continued
Total 2000–2004 2005–2009
p-value
n % n % n %
Any treatment <0.001
Treatment 3237 33 1331 31 1906 34
No treatment 6623 67 2967 69 3656 66
Stage at diagnosis <0.001
Localized 4522 46 1776 41 2746 49
Regional 2442 25 1063 25 1379 25
Distant 1577 16 728 17 849 15
Unstaged 1319 13 731 17 588 11
† Cells with values less than 11 are not presented
2.3.4 Stage at diagnosis over time
Stage at diagnosis changed significantly between the two time periods, with diagnosis at earlier
stages in the later time period compared to the earlier time period (p < 0:001) (Table 2.1). In the
time period from 2000 to 2004, 42% of HCC cases were localized and 17% were distant compared
to 49% localized and 17% distant in the time period from 2005 to 2009. When unstaged cases were
excluded, the proportion of cases diagnosed with HCC at an earlier stage remained higher in the
later time period
2.3.5 Stage at diagnosis by risk factor over time
Change in stage at diagnosis over time was significant in all HCC cases with more cases being
diagnosed at an earlier stage. The relative risk of diagnosis at localized stage in the later time period
compared to the earlier time period was 1.15 (CI: 1.11,1.19) for all HCC cases. This difference held
across risk groups, but was significant only in those with hepatitis C infection, hepatitis B infection,
diabetes, cirrhosis, and no risk. The range of relative risk of diagnosis in an earlier stage was 1.03
to 1.25 suggesting an increase in earlier diagnosis in all groups over time. The risk groups with
screening recommendations include at least some of those with HBV infection, HCV infection, and
cirrhosis. The relative risk for the HBV group (1.25, CI: 1.07,1.46) and the cirrhosis (1.19, CI:
1.11,1.27) group was slightly higher than in the other risk groups, but the relative risk in the HCV
group (1.10, CI: 1.02,1.20) was lower than that of the group with no identified risk.
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Table 2.2: Risk of being diagnosed at localized stage in 2005–2009 compared to 2000–2004
Race Relative risk 95% CI
All HCC cases 1.15 1.11,1.19
Hepatitis C 1.10 0.92,1.20
Hepatitis B 1.25 1.07,1.46
Obesity 1.12 0.95,1.32
Diabetes 1.16 1.11,1.22
Tobacco use 1.04 0.91,1.18
Alcohol abuse 1.03 0.90,1.18
Cirrhosis 1.19 1.11,1.27
No risk 1.14 1.06,1.22
Table 2.3: Median survival after diagnosis by stage in days by risk factor
Median survival
without identified risk
Median survival
with identified risk
Days 95% CI Days 95% CI
All HCC cases 178 170,187 NA
Hepatitis C 158 151,167 340 310,380
Hepatitis B 169 161,177 554 440,703
Obesity 178 170,188 166 128,229
Diabetes 183 171,195 174 162,186
Tobacco use 180 171,189 142 120,172
Alcohol abuse 180 171,189 160 140,197
Cirrhosis 163 156,173 236 215,258
2.3.6 Survival
The results of the Kaplan-Meier analysis showed differences in median survival for those with and
without certain risk factors. Median survival for the HCC cohort was 178 days after diagnosis and
varied between those with and without HBV infection, HCV infection, and cirrhosis. Median sur-
vival was significantly longer in those with HBV at 554 days (CI: 440,703) compared to 169 days
(CI: 161,177) in those without HBV. Those with HCV and cirrhosis also had longer median sur-
vival. The median survival for those with HCV was 340 days (CI: 310,380) compared to 158 days
(CI: 151,167) those without HCV and 236 days (CI: 215,258) in those with cirrhosis and 163 days
(CI: 156,173) without cirrhosis. There was no significant difference in survival in any other risk
group (Table 2.3).
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Table 2.4: Median survival by diagnosis group in days
2000–2004 2005–2009
Days 95% CI Days 95% CI
All HCC cases 146 136,154 213 198,226
Hepatitis C 304 254,374 361 320,413
Hepatitis B 371 255,501 761 574,938
Obesity 126 66,201 194 134,279
Diabetes 143 124,156 205 183,225
Tobacco use 144 95,192 141 114,187
Alcohol abuse 118 94,156 175 156,247
Cirrhosis 186 153,214 267 240,299
2.3.7 Survival over time
Median survival varied significantly by time period with longer survival in the later diagnosis group
(Table 2.4). Median 5-year survival was 146 days (CI: 136,154) in those diagnosed from 2000
to 2004 and 213 days (CI: 198,226) in those diagnosed from 2005 to 2009. Survival increased
significantly between the first and second time period within three risk groups: HBV, diabetes, and
cirrhosis. The largest increase was in those with identified HBV, from 371 days (CI: 255,501) in
the first time period to 761 days (CI: 574,938) in the second time period representing an increase of
over a year. There was no significant difference seen between the two time periods for those with
HCV, obesity, tobacco use, or alcohol abuse.
2.4 Discussion
The results of our analysis are consistent with previous work looking at changes in the proportion of
cases of HCC with HCV infection. Two previous studies found increases in the proportion of HCC
cases with HCV over time.60,61 The results of this analysis indicate that this trend is continuing from
the early 2000s through the late 2000s. This is consistent with the burden from disease of HCV
infection in the United States. The first members of the birth cohort with the highest prevalence
of HCV turned 65 years old and became Medicare-eligible due to age in 2010, so increasing HCV
infection in the Medicare population will likely continue to increase the proportion of HCC cases
with HCV over the next 20 years.
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The proportion of cases with HCV infection found in this analysis differed from results in pre-
vious analyses.60,61 We found that 13% of HCC cases from 2000 to 2004 and 17% of HCC cases
from 2005 to 2009 had evidence of HCV infection while previous estimates for HCV among those
with HCC in the SEER-Medicare matched data set found up to 23% with HCV. This is likely due
to differences in case counting. For this analysis we included only one year of claims before HCC
diagnosis. In other studies, longer time frames up to three years before diagnosis have been used.
The same ICD-9 codes were used for this analysis as were used for previous analyses. A sensitiv-
ity analysis was performed using additional years of claims data to identify hepatitis C, and similar
rates were identified as in other analyses. The decision to use only one year of claims was based
on the ability to include persons as young as 66 years of age in the analysis (See Appendix C, HCV
case-counting limitations). Despite these differences, the trend is consistent across the three analy-
ses using this data set. The results from previous analyses used different divisions of time periods
with one using two 3.5-year periods and the other using two 6-year periods.60,61 For this analysis,
the time period was split into two equal five year time periods. A sensitivity analysis was done using
year of diagnosis as a continuous predictor and no differences were seen in the trends in risk factors
over time.
The proportion of female HCC cases varied by risk factor indicating potential differences in
HCC risk factors by gender. These findings were consistent with findings in previous studies.60,61
This analysis was not intended to determine causes of HCC by gender and further investigation into
gender specific risks for HCC would be needed to better understand the causes and implications of
these differences.
In addition to the differences in the proportion of HCC cases with a history of HCV infection,
we found an increase in the proportion of cases with any reported HCC risk. The proportion of
cases with no risk decreased from 39% to 31%. There was also an increase in those with multiple
risk factors identified. The risk factors with the largest increase between the two time periods were
hepatitis C, cirrhosis, and diabetes. With all risk factors measured increasing over the time of this
study, it is possible that there is a change in the population being diagnosed with HCC or a change
in documentation of these risk factors in the Medicare claims. Welzel et al. recently described the
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population-attributable fraction, a measure of both the prevalence of the risk factor in the population
and the strength of the association between the risk factor and the outcome, for risk factors for HCC
using the SEER and Medicare linked data. They found that the population-attributable fraction was
greatest for obesity and diabetes in this population.61When combinedwith the results of this analysis,
these findings point to at least two potential interventions to reduce the morbidity and mortality
associated with HCC in this population. The first, as suggested by Welzel et al., would be to reduce
obesity and diabetes in the entire population to reduce the incidence of HCC in the long term.61 The
second would be a targeted approach to identify persons with HCV infection and HBV infection,
assure consistent care for their liver disease including identification of cirrhosis, and screening for
HCC. These two approaches combined could reduce the incidence of HCC and potentially improve
the outcomes from HCC in this population in the near and distant future.
The increasing proportion of cases with a previously identified risk factor is promising for at-
tempts to identify HCC at an earlier stage. Screening is recommended for persons with cirrhosis and
HCV infection or HBV infection. We found that HCV infection, HBV infection, and cirrhosis were
all associated with diagnosis at an earlier stage. We were not able to measure screening directly, so
the role it played in this association is unknown, but screening would be a reasonable explanation
for this finding. When examined across time, the relative risk of being diagnosed with localized
HCC in the second time period when compared to the first time period was significantly greater than
one for all three of these risk factors. The increase among those without any identified risk factor
was also greater than 1 and was significant. This indicates that there was a small increase in those
diagnosed in the earlier stage for each group over time, but that there were not major differences in
improvements in early identification between those with an identified risk and those with no iden-
tified risk. The other risk factors examined were associated with shorter survival after diagnosis,
but these differences were not significant. Interpretation of the differences in survival in those with
tobacco use, obesity, and alcohol abuse in this analysis is limited by the likely underreporting of
these risks in the claims data. The findings in this analysis point to a potential difference in survival
between those with viral hepatitis infection and those with behavioral risk factors. If those with
behavioral risk factors not documented in the Medicare claims make up a large proportion of those
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without an identified risk, the apparent protective effect of HCV infection and HBV infection on
survival may be explained by difference between those with viral hepatitis infection and those with
behavioral risk factors.
Identification at an earlier stage is only important if there are differences in outcomes in those
who are identified earlier. We were able to demonstrate that those diagnosed at an earlier stage
live significantly longer than those who were diagnosed at any other stage. Those diagnosed in the
localized stage lived a median of 295 days longer than those diagnosed at a distant stage. This is a
meaningful difference in the context of a range of median survival of 77 to 372 days after diagnosis,
but may be due to earlier detection in cases that are screened rather than coming to detection due
to symptoms. Over the time period examined in this analysis, we found that survival increased
significantly. The median survival in the earlier group was 67 days shorter than in the later group.
These gains were seen in both the treatment and no treatment group, so this difference cannot be
attributed to treatment alone. Survival improved over time for those with all examined HCC risk
factors except tobacco use which remained almost the same (144 days for 2000–2004 and 141 for
2005–2009). For those risk factors where there was an increase in survival, the increase in survival
was similar for all risks except HBV infection. Survival for those with HBV doubled from 371
days for 2000–2004 to 761 days for 2005–2009. Some of this difference is explained by stage at
diagnosis as HBV cases had the largest increase in cases diagnosed with localized HCC over time.
Other factors such as liver health likely play a role in the increase, but were not measured in this
analysis.
Measuring risk factors in the Medicare claims data presents many challenges. It is likely that
there are some enrollees who have one or more of the risk factors but have no record of these risk
factors in the claims data. This is likely especially true for obesity, tobacco use, and alcohol abuse.
These are not necessarily conditions that would be documented for a visit even if the condition were
present. Given these limitations, these risk factors were likely undercounted. The trends seen with
the cases found should still be considered as an indication of potential changes over time. For HCV
infection, HCV-related factors and liver health indicators were not available. Cancer staging for
HCC is based on factors not measured in SEER. Stage was used to approximate disease progression,
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but the BCLC staging recommended by the American Association for the Study of Liver Diseases
was not used.62 Despite these limitations, our findings add to the available information on HCV and
other risk factors for HCC in the Medicare population.
In conclusion, both the population with HCC among Medicare beneficiaries and the outcomes
of those with HCC are changing over time. Increases in the proportion of cases of HCC with HCV
infection in this population are consistent with previous studies. Despite an increasing proportion
of cases diagnosed at earlier stages, increases in HCV treatment over time were minimal. This
demonstrates opportunities for better HCC outcomes if new therapies become available.
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Chapter 3
Differences in hepatocellular carcinoma
by hepatitis C status in Medicare
beneficiaries
Context Liver-cancer incidence and mortality are increasing in the United States and hepatitis C
is a likely contributor to that increase. The increasing age and duration of infection of the
population with hepatitis C has the potential to increase the number of Medicare beneficiaries
with HCC caused by hepatitis C over the next 20 years.
Objective To describe the outcomes of persons with a diagnosis of HCC who are infected with
HCV compared to those who are not infected with HCV
Design Cohort study
Setting SEER-Medicare matched data
Patients Cases of hepatocellular carcinoma diagnosed 2000 to 2009 and reported to SEER
Main outcome measure All-cause and liver-cancer-specific mortality
3.1 Introduction
HCC, the most common liver cancer, is one of the potential long-term consequences of HCV infec-
tion. Certain persons with HCV infection are more likely to get HCC, including men, older persons,
persons who use large amounts of alcohol, persons with hepatitis B infection, persons with HIV, and
those with evidence of cirrhosis.29 Estimates of the prevalence of HCC in those with chronic HCV
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infection range from 4% to 9% after 10 to 40 years of infection.30,31 Unfortunately, liver-cancer
incidence continues to increase and increased from 5.0 per 100 000 in 1999 to 7.1 per 100 000 in
2010.59 The American Cancer Society estimates that the 5-year relative survival rate for localized
HCC is 28%, for regional HCC it is 10%, and for distant spread it is 3%.75 HCC screening using
ultrasound is recommended for persons with HCV infection with cirrhosis due to elevated risk of
HCC.62
Past studies examining the outcomes of HCC looked at outcomes of persons with HCV infec-
tion and HCC compared to others with HCC alone and found somewhat conflicting results. Reddy
et al. compared HCC cases with HCV infection to those with nonalcoholic steatohepatitis and found
that HCV infected patients had a shorter overall survival time, but not a significant difference in
recurrence-free survival after curative therapy.44 Takuma et al. found that persons with HCV and
HCC in Japan had lower rates of recurrence and lower mortality than those with cirrhosis of an un-
known cause and HCC.45 In contrast, Lee et al. found no difference in survival or treatment between
Korean patients with HCV-associated HCC and those with cryptogenic-cirrhosis-associated HCC.76
In addition, in a study examining the roll of viral load in determining outcomes of HCC after resec-
tion, Shindoh et al. found that Japanese patients with low viral load had better long-term outcomes
after resection.46 Other studies have looked at outcomes for persons with HCC, but not looked at
HCV-infected patients specifically.
The prevalence of HCV infection varies by age in the United States with the highest rates of
reported infection occurring in those born in the 1940s, 1950s, and 1960s.6 In 2012, CDC recom-
mended screening for all persons born between 1945 and 1965.6 Data from NHANES was used
to estimate the number of cases of chronic hepatitis C in this cohort at 2.06million.6 This repre-
sents 54–77% of the total estimated infections in the United States, while this age group makes up
only 11% of the U.S. population.1,6,7 Persons born in the early part of this cohort are now eligible
for Medicare. Two previous studies using the SEER cancer registry and Medicare-linked database
found that the proportion of HCC cases with HCV infection had increased during the 1990s and
early 2000s.60,61 As the population with the highest prevalence of HCV infection reaches Medicare
age, the SEER-Medicare database could become more useful as a tool to explore the outcomes of
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HCC in persons with HCV infection. In this paper, we will use the SEER-Medicare data to look at
differences in treatment for liver cancer, liver cancer mortality, and 5-year survival in HCC cases
with and without HCV infection.
3.2 Methods
3.2.1 Data
This analysis was conducted using SEER data linked toMedicare claims data. SEER is a surveillance
system made up of a number of population-based tumor registries in states and metropolitan areas.
For cases diagnosed in 2000 and later, SEER registries cover 27% of the U.S. population.70,71 Data
are collected on demographic, clinical, and cause-of-death information for persons with cancer in
these areas. The data are then linked withMedicare claims and distributed by the National Cancer In-
stitute (Calverton, MD).72 The cohort for this analysis was persons who were Medicare-enrolled and
diagnosed with hepatocellular carcinoma between 2000 and 2009. Medicare claims were available
through 2010. Louisiana SEER registry data from 2005 were excluded due to data-collection issues
following hurricane Katrina. Rural Georgia SEER registry data were excluded from the analysis
due to the small sample size.
3.2.2 Case selection
HCC cases were selected from the SEER database for diagnoses between 2000 and 2009. HCC
cases were defined using International Classification of Disease for Oncology codes 8170–8172,
8174–8175, and 8180. All HCC cases diagnosed at age 66 or older with current enrollment based
on age were included.
Hepatitis C cases were selected using ICD-9 codes for hepatitis C (i.e., 070.41, 070.44, 070.51,
070.54, 070.70, and 070.71). Diagnosis for hepatitis C and other risk factors were defined as one
MedPar diagnosis code or two OP/NCH diagnosis codes on two separate dates. Other risk factors
for HCC were found using ICD-9 codes (Appendix B).
We limited cases to those who were likely to have complete claims. That is, they had at least one
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year of continuous enrollment in Part A and Part B before the HCC. The cohort was limited to those
not enrolled in a health maintenance organization. Cases without a diagnosis date or any Medicare
claims prior to diagnosis were excluded. Cases with dates of death or dates of birth varying by more
than three months between the SEER death date andMedicare death date were excluded. We limited
our cohort to those reported through hospitals, radiation treatment centers or medical oncology cen-
ters, laboratories, physician’s offices, and hospital outpatient units or surgery centers. We excluded
cases who were diagnosed based on death certificate, autopsy, or nursing home reporting only.
3.2.3 Treatment
First course of treatment for HCC included surgical resection, radiation, chemotherapy, and/or liver
transplant. We used SEER variables for surgical resection (sxprif1–sxprif10) and radiation (rad1–
rad10). Surgery was defined as surgery of the primary site using the site-specific codes for liver and
intrahepatic bile ducts.73 Radiation therapy was defined as having received radiation therapy for the
liver cancer instance. Chemotherapy was found in the Medicare Outpatient (OP) and Carrier (NCH)
files during the first six months after diagnosis and was defined as Healthcare Common Procedure
Coding System (HCPCS) codes 96400–96549 and Q0083–Q0085.74 Cases with an ICD-9 code of
V42.7 (liver replaced by transplant) or 996.82 (complications of transplanted liver) in the Medicare
Hospitalization (MedPar) file within three months of diagnosis were considered to have received a
liver transplant as part of cancer treatment.
3.3 Cancer characteristics
Tumor characteristics were obtained from SEER sources. For cancer stage, SEER historic stage
(i.e., localized, regional, distant, and unstaged) was used because the American Joint Committee on
Cancer (AJCC) stage was unavailable for a third of the cases. Historic stage and AJCC stage were
largely consistent. The majority of HCC cases in the analysis data set were not histologically con-
firmed. Size of tumor was calculated from two different variables depending on the year diagnosed
(extent of disease tumor size for cases before 2004 and collaborative stage tumor size from 2004 on)
and were combined into six categories: no tumor found, <1 cm, 1–2 cm, 2–3 cm, >3 cm, and un-
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known tumor size. We did not include information in our analysis about grade as it was unavailable
for 59% of cases.
3.3.1 Outcomes
All-cause mortality and cancer-specific mortality were measured at five years after diagnosis. Date
of death is obtained from Medicare sources as SEER sources include month and year of death only.
Persons who were deceased according to the Medicare date of death were further classified by cause
of death using the cause of death to site recode variable from SEER. Each case of HCCwas classified
as alive or dead and cases that had died and had cause of death information were classified as liver-
cancer-related deaths and deaths from other causes. Specific days-to-death variables were created for
liver cancer and all causes. Cases were censored at the most recent claim file date and at death from
other causes for the liver-cancer-related death analysis. Persons alive after 5 years were censored as
were persons with less than 5 years of follow up as of December 31, 2011.
3.3.2 Analysis
Data were analyzed using SAS 9.3 (SAS Institute, Cary, NC). We compared the frequency of each
of the relevant predictors using chi-squared tests. A Kaplan-Meier analysis was used to calculate
survival at 5 years stratified by HCV infection status and log-rank testing was used to determine
statistical significance. Cox proportional hazard models were used to examine the effect of HCV
infection status adjusted for age, gender, and other risk factors for HCC on mortality. We stratified
the Cox proportional hazard models by stage at diagnosis and age to further explore the relationship
between HCV infection and HCC outcomes within groups.
3.4 Results
The linked SEER-Medicare data contained 9860 cases of HCC diagnosed between 2000 and 2009
that met the criteria for inclusion in this analysis (Table 3.1). Of the total number of HCC cases,
1505 (15%) had a diagnosis of hepatitis C infection. The annual number of cases of HCC increased
from 719 in 2000 to 1166 in 2009, while the percent of cases with HCV infection has increased
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from 10% of all HCC cases in 2000 to 18% of all HCC cases in 2009. Cases of HCC with HCV
infection were more evenly divided between genders (56% male compared to 69% male with HCC
without HCV infection, p < 0:001). The median age of HCC cases with HCV infection was younger
compared to those without HCV infection (73.5 years versus 75.9 years, p < 0:001). Documented
cirrhosis varied between HCC cases with and without HCV infection. Just over half of HCV infected
HCC cases had cirrhosis documented while only 19% of HCC cases without HCV infection had
documented cirrhosis (p < 0:001). The percent of HCV cases with cirrhosis documented was lower
than expected, so an additional cirrhosis measure was added for cirrhosis reported from 12 months
beforeHCCdiagnosis through the end of the claims data. The proportion of HCC caseswith cirrhosis
increased when measured after HCC diagnosis and remained higher in HCV cases (84% of those
with HCV infection and 48% of those without HCV infection, p < 0:001); see Appendix G.
The most common stage at diagnosis was localized for both groups, while the percent unstaged
is similar across groups (11% unstaged in those with HCV infection and 14% unstaged in those
without HCV infection). HCC cases with HCV infection were diagnosed at earlier stages than HCC
cases without HCV infection (Table 3.1). Tumor size was missing for 32% of cases. HCC cases
with HCV infection were more likely to have a tumor size of less than 1 cm (70% compared to
50% for HCC cases without HCV infection). Only 33% of HCC cases received treatment, with
the highest treatment rates in those with localized and regional cancer stage at diagnosis (Table 3.1).
HCV-infected cases were more likely to be treated than others at every stage. Given earlier stage
at diagnosis, this resulted in HCV-infected cases having higher treatment rates. The most common
treatment type was surgery (21%), followed by chemotherapy (11%) and radiation (5%). Treatment
type varied by HCV infection status with surgery occurring more commonly in those with HCV
infection (30% in HCV cases and 19% in HCC cases without HCV infection, p < 0:001). A
stratified analysis revealed that HCV-infected cases weremore likely to be treated at every diagnostic
stage but distant (Table 3.3). Treatment type also varied by stage at diagnosis. For localized and
regional stages, surgery was the most common treatment (30% for localized, 13% for regional, 4%
for distant, and 5% for unstaged). Radiation was most common at distant stage (3% of localized,
3% of regional, 10% of distant stage, and 1% of unstaged).
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Figure 3.1: Treatment by stage at diagnosis
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Table 3.1: Case characteristics of hepatocellular carcinoma cases by HCV infection status
Total Not HCV case HCV case
p-value
n % n % n %
HCC cases 9860 8355 1505
By gender <0.001
Male 6574 67 5731 69 843 56
Female 3286 33 2624 31 662 44
By race <0.001
White 6863 70 6006 72 857 57
Black 774 8 601 7 173 12
Other 504 5 395 5 109 7
Asian 1206 12 917 11 289 19
Hispanic 420 4 353 4 67 4
American Indian‡ NA NA NA
Unknown‡ NA NA NA
By age at diagnosis <0.001
65–69 1925 20 1499 18 426 28
70–74 2680 27 2213 26 467 31
75–79 2525 26 2157 26 368 24
80–85 1762 18 1581 19 181 12
85+ 968 10 905 11 63 4
By HBV status <0.001
HBV case 495 5 382 5 113 8
Not HBV case 9365 95 7973 95 1392 92
By status at 5 years <0.001
Living 1002 10 792 9 210 14
Deceased 8858 90 7563 94 1295 86
By cause of death 0.135
Died of liver cancer 5707 71 4921 71 786 69
Died of other causes 2373 29 2016 29 357 31
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Table 3.1, continued
Total Not HCV case HCV case
p-value
n % n % n %
By year diagnosed <0.001
2000 719 7 650 8 69 5
2001 778 8 699 8 79 5
2002 861 9 730 9 131 9
2003 938 10 797 10 141 9
2004 1002 10 858 10 144 10
2005 1060 11 877 11 183 12
2006 995 10 820 10 175 12
2007 1166 12 969 12 197 13
2008 1175 12 996 12 179 12
2009 1166 12 959 11 207 14
Percent of census tract below poverty level 0.003
<13.8% 6405 65 5493 66 912 61
13.8–19.9% 1358 14 1117 13 241 16
20–39.9% 1737 18 1448 17 289 19
40% 258 3 210 3 48 3
Unknown 102 1 87 1 15 1
Median census tract income 0.03
Below U.S. median <42 128 4374 44 3712 44 662 44
Above U.S. median >42 128 5260 53 4438 53 822 55
Unknown 226 2 205 2 21 1
Stage <0.001
Localized 4522 46 3679 44 843 56
Regional 2442 25 2098 25 344 23
Distant 1577 16 1431 17 146 10
Unstaged 1319 13 1147 14 172 11
Histology 0.26
8170 9651 98 8169 98 1482 98
8171‡ 16 NA NA
8172‡ 14 NA NA
8174‡ 91 NA NA
8175‡ NA NA NA
8180 85 1 73 1 12 1
Grade <0.001
I 1447 684 13 763 17
II 1548 628 21 920 21
III 953 498 10 455 10
IV 86 42 1 44 1
Cell type not determined, 5826 3613 66 2213 50
not stated or not applicable
Tumor size <0.001
No tumor found‡ NA NA NA
<1 cm 5226 53 4176 50 1050 70
1–2 cm 1364 14 1287 15 77 5
2–3 cm‡ 67 1 NA NA
>3 cm‡ 26 0 NA NA
Unknown 3169 32 2798 33 371 25
34
Table 3.1, continued
Total Not HCV case HCV case
p-value
n % n % n %
Treatment
One or more treatments <0.001
Any treatment 3237 33 2603 69 634 42
No treatment 6623 67 5752 31 871 58
Surgery <0.001
Surgery 2034 21 1583 19 451 30
No surgery 7826 79 6772 81 1054 70
Radiation 0.88
Radiation 471 5 398 5 73 5
No radiation 9389 95 7957 95 1432 95
Chemotherapy 0.12
Chemotherapy 1042 11 866 10 176 12
No chemotherapy 8818 89 7489 90 1329 88
Multiple treatments NA
Chemotherapy and 214 2 170 2 44 3
surgery
Chemotherapy and 42 0 NA NA
radiation‡
Surgery and radiation‡ 44 0 NA NA
Chemotherapy, surgery, NA NA NA
and radiation‡
‡ Cells with values less than 11 are not presented
3.4.1 Overall 5-year survival
At five years after HCC diagnosis, only 9% of those without HCV infection and 14% of those
with HCV infection were still living (p < 0:001) (Figure 3.2). Cases of HCC with hepatitis C
infection had better unadjusted overall 5-year survival than those without HCV infection (HR =
0:74, p < 0:001). HCC cases with hepatitis B infection also had higher unadjusted overall 5-year
Table 3.2: Percent treated by HCV infection status stratified by stage at diagnosis
Stage Percenttreated
Percent
treated not
HCV case
Percent
treated
HCV case
p-value
Localized 45 42 52 <0.001
Regional 30 28 37 <0.001
Distant 22 22 24 0.629
Unstaged 13 12 19 0.016
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Figure 3.2: Overall 5-year survival by hepatitis C infection status
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Table 3.3: Median survival by stage in days unadjusted
Stage No HCV HCV Differencein days p-valueDays 95% CI Days 95% CI
Localized 338 317,361 527 475,614 189 <0.001
Regional 137 126,150 266 216,328 129 <0.001
Distant 77 70, 82 77 61,101 0 0.23
Unstaged 98 86,106 160 97,192 62 0.052
survival (HR = 0:52, p < 0:001). HCC cases who were treated had higher unadjusted overall 5-year
survival rates than those who did not have treatment (HR = 0:36, p < 0:001). Stage at diagnosis
significantly impacted overall survival with the lowest survival in those diagnosed at distant stage
(HR = 3:00, p < 0:001 compared to localized). The results of the Kaplan-Meier analysis by
stage showed a significant advantage for HCV-infected cases compared to HCC cases without HCV
infection in survival in days in localized and regional stages only (Table 3.3). Localized HCC cases
with HCV infection had a median survival after diagnosis of 189 days longer than those without
HCV infection.
When adjusted for stage, race, gender, age at diagnosis, treatment, diabetes, cirrhosis, year of
diagnosis, and hepatitis B status, hepatitis C infection was still significantly associated with better
overall survival (HR = 0:87, p < 0:001) (Table 3.4). The proportional hazards assumption was
violated for this model, but the results are presented here without correction. Hepatitis C was signif-
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Table 3.4: Cox proportional hazard models with covariates for 5-year all-cause mortality
Predictor HR p-value
HCV infection 0.87 <0.001
Stage at diagnosis <0.001
Localized Reference
Regional 1.60
Distant 2.55
Unstaged 1.59
Race <0.001
White Reference
Black 1.15
Other 0.87
Asian 0.78
Hispanic 0.95
American Indian 1.12
Unknown 0.96
HBV infection 0.70 <0.001
Male 1.00 1.00
Age at diagnosis <0.001
65–69 Reference
70–74 1.09
75–79 1.16
80–85 1.22
85+ 1.42
Receipt of one or more treatment 0.41 <0.001
Diabetes 1.10 <0.001
Cirrhosis 1.10 0.005
Year diagnosed 0.97 <0.001
icantly associated with better overall survival in both the corrected and uncorrected versions. See
Appendix H for a Cox proportional hazard model with corrections. When stratified by stage, ad-
justed overall 5-year survival was only significant in the regional stage (HR = 0:81, p = 0:005).
There was no significant difference at any other stage, but the hazard ratios remained below one
for all stages (Table 3.5). When stratified by age, HCV infection was significantly associated with
better survival in the three youngest age groups, but not the two oldest (Table 3.6).
3.4.2 Death from liver cancer at five years
Of those HCC cases deceased at five years post diagnosis, 69% of HCV-infected cases and 71%
of those without HCV infection died from their liver cancer (p = 0:494). The four most common
causes of death in those who did not die of their HCC were other cancers, diseases of the heart,
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Table 3.5: Stage-stratified Cox proportional hazard models adjusted for 5-year all-cause mortality
Stage HR p-value
Localized 0.91 0.05
Regional 0.81 <0.001
Distant 0.87 0.133
Unstaged 0.88 0.131
Table 3.6: Age-stratified Cox proportional hazard models adjusted for 5-year all-cause mortality
Age at diagnosis HR p-value
65–69 0.80 <0.001
70–74 0.84 0.002
75–79 0.83 0.004
80–85 0.93 0.424
85+ 0.83 0.174
liver diseases and cirrhosis, and infectious and parasitic diseases including HIV. Cases of HCC with
hepatitis C infection have a lower risk of dying from liver cancer in the first five years after diagnosis
(HR = 0:73, p < 0:001). Earlier stage at diagnosis (localized compared to distant, HR = 0:44,
p < 0:001), younger age (youngest compared to oldest age group, HR = 0:71, p < 0:001), hepatitis
B infection (HR = 0:72, p < 0:001), cirrhosis (HR = 0:89, p < 0:001), and receipt of one or more
treatment (HR = 0:42, p < 0:001), were significantly associated with lower risk of dying from liver
cancer at five years. Those with diabetes (HR = 1:04, p = 0:20) had an increased risk of dying
from liver cancer. Risk of death increased over time (HR = 1:06, p < 0:001). The risk of dying
from liver cancer at 5 years varied by race (p < 0:001). Male sex (HR = 0:98, p = 0:573) was not
significantly associated with liver-cancer death.
When adjusted for stage, race, gender, age at diagnosis, treatment, diabetes, cirrhosis, year of
diagnosis, and hepatitis B status, the HCV association with liver-cancer death remains statistically
significant (HR = 0:83, p = 0:001) (Table 3.7). Cirrhosis (HR = 1:01, p = 0:77) and age at
diagnosis (p = 0:13) were not significantly associated with lower risk of liver-cancer death in the
adjusted model. All other predictors remained significantly associated with liver-cancer death in the
adjusted model.
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Table 3.7: Cox proportional hazard models with covariates for 5-year liver-cancer mortality
Predictor HR p-value
HCV infection 0.85 <0.001
Stage at diagnosis <0.001
Localized Reference
Regional 1.55
Distant 2.05
Unstaged 1.50
Race 0.002
White Reference
Black 1.10
Other 0.96
Asian 0.88
Hispanic 0.88
American Indian 1.31
Unknown 0.68
HBV infection 0.83 0.009
Male 0.97 0.249
Age at diagnosis 0.131
65–69 Reference
70–74 1.07
75–79 1.06
80–85 1.07
85+ 1.15
Receipt of one or more treatment 0.46 <0.001
Diabetes 1.08 0.006
Cirrhosis 1.01 0.766
Year diagnosed 1.05 <0.001
3.5 Discussion
Survival differs betweenMedicare beneficiaries withHCCwith evidence ofHCV infection and those
without evidence of HCV infection. HCC cases with HCV infection have higher 5-year survival and
fewer deaths from liver cancer in the first 5 years after diagnosis. Differences in stage at diagnosis
and likelihood of treatment may explain some, but not all, of these differences. When stratified
by stage, the association between HCV infection status and survival was only significant in those
diagnosed at regional stage.
Screening for HCC using abdominal ultrasound is recommended for persons with HCV with
cirrhosis based on the elevated risk for HCC in that population.62,77 Our findings likely reflect this
recommendation as persons with HCV infection were diagnosed at earlier stages and smaller tumor
sizes. HCC screening was not measured in this study, so the relation between HCC screening and
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stage at diagnosis could not be determined directly, but screening would be a likely cause of the
observed pattern of earlier stage at diagnosis and smaller tumors. This is consistent with other studies
looking at HCC screening and stage at diagnosis.78,79 It is also possible that both patient and provider
awareness of risk of HCC may cause patients to seek evaluation and providers to suspect HCC at
a lower threshold than for patients without an identified risk for HCC. This further supports the
recommendation for screening in those with HCV infection and cirrhosis.
In most cases, HCC due to hepatitis C infection is thought to occur as a result of cirrhosis of
the liver, but there is some evidence that HCC can occur in the absence of cirrhosis in some persons
with HCV infection.29,80,81 In this population, only 51% of HCV-infected cases had cirrhosis docu-
mented before HCC diagnosis and 84% overall. Although this was higher than in those with HCC
alone, there were still cases without documented cirrhosis among those with HCV infection. It is
possible that cirrhosis was present in a higher proportion of the HCV cases, but it was not present
in the claims data used. In almost half of those with HCV, cirrhosis appears to have been identified
after cancer diagnosis rather than before. This raises the possibility of a difference in cases with clin-
ically relevant cirrhosis likely found before HCC diagnosis and cirrhosis discovered at or after HCC
diagnosis. Ongoing screening for HCC is recommended for persons with HCV infection only in the
presence of cirrhosis. If cirrhosis is present in all or nearly all HCC cases among those with HCV
infection, it appears that many of these cases had undiagnosed cirrhosis. Answering the question of
whether HCC is occurring in the absence of cirrhosis was beyond the scope of this analysis, but the
answer could further the understanding of HCC in persons with HCV infection and recommendation
for screening for HCC in persons with HCV infection.
We found that treatment for HCC was associated with better overall 5-year survival and lower
mortality at 5 years from liver cancer. This difference remained significant even when adjusted for
stage at diagnosis. The effect of treatment on 5-year survival did not vary based on HCV infection
status based on the results of the stratified analysis. Based on these results, it appears that hepatitis
C infection is not associated with a decreased response to therapy. Evidence from a previous study
indicates that higher viral load is associated with poorer outcomes after surgical resection.46 Fur-
ther investigation of the association between viral load and HCC outcomes may find differences in
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outcomes within HCV-infected HCC cases.
This study is based on data from a population-based cancer registry, SEER, which includes some
of the risk factors for HCC, treatments for HCC, and information on cause of death for those who
died. There are a number of limitations to the information available in the registry. Some risk fac-
tors such as obesity, tobacco use, and rare disorders are poorly documented in Medicare claims data
and were not included in this analysis. In addition, HCV-related factors such as viral load, geno-
type, and mutations and liver-health indicators such as blood bilirubin level and Child-Pugh score
were not available from SEER or Medicare sources, and grade was missing in a large proportion
of cases. Stage was used to approximate disease progression at diagnosis, but outcomes could not
be examined based on the BCLC staging recommended by the American Association for the Study
of Liver Diseases because the SEER cancer registries do not collect them.62 For example, BCLC
staging takes Child-Pugh score, portal hypertension, and blood bilirubin levels into consideration.
These factors as well as grade may prove to be important in identifying persons with HCV infections
who are more or less likely to respond to treatment. Despite these limitations, the findings of this
analysis provide further information on the outcomes of HCC in the United States.
In conclusion, there is variation in 5-year mortality among HCC cases with and without HCV
infection and it appears to occur primarily in those diagnosed at regional stage. The reasons for this
are unclear, but treatment differences and earlier diagnosis may play a role. Treatment only occurs
in a small proportion of HCC cases even in those diagnosed in early stages. Improvements in HCC
treatment are needed to change the outcomes of HCC in those with and without HCV infection.
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Chapter 4
The effect of current treatments for
hepatitis C on mortality from hepatitis C
in persons born between 1945 and 1965,
United States
Context New HCV treatments were licensed in 2011 and 2013, with more expected in the future.
With better treatments available and many years of surveillance data and HCV experience,
some state and local health departments are considering whether to implement strategies to
assist HCV-infected persons in finding appropriate health care. If these projects are under-
taken, they will have to fit into systems with limited resources. Information is needed on
how to prioritize cases, as only a small percentage of cases would be able to be targeted for
intervention.
Objective To model the effect of treatments for HCV on patient and population outcomes and to
identify persons who should be highest priority for linkage to care programs based on the
impact of the health of the population
Design State-transition model of disease progression with a transmission component and parameter
estimates derived from the literature
Setting United States
Patients People born between 1945 and 1965
Main outcome measures Mortality fromHCV infection, remaining life years, newHCV infections
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4.1 Introduction
HCV is the most common blood-borne infection in the United States, with an estimated 2.7million
to 3.9million Americans living with chronic HCV infection1 and about 16 500 new HCV infections
annually.2 Chronic HCV infection occurs in the majority of those initially infected and can lead to
cirrhosis, hepatocellular carcinoma, and death. The prevalence of HCV infection varies by age in
the United States with the highest rates of reported infection occurring in those born in the 1940s,
1950s, and 1960s.6 In 2012, CDC recommended screening for all persons born between 1945 and
1965.6 The estimated number of cases of chronic HCV in this cohort is 2.06million.6 This represents
54% to 77% of the total estimated infections in the United States, while this age group makes up
only 11% of the U.S. population.1,6,7
The most commonly reported risk factor for HCV infection in the United States is injection
drug use.2 The percentage of reported cases of new HCV infection reporting injection drug use
is higher in younger persons. In those over 40 years of age, injection drug use is the third most
frequently reported risk factor after surgery and multiple sexual partners.82 However, injection drug
use is considered to be a higher risk behavior. There is currently no vaccine available for HCV, and
prevention consists of encouraging safer injection practices or discontinuation of injection drug use.
Continued use of sterile medical equipment, testing of the blood and organ supply, and universal
precautions are also prevention strategies.
Treatment for HCV infection has been available for over two decades and has improved dramat-
ically over that time. The goal of HCV treatment is an undetectable viral load at six months after
treatment, which is referred to as a SVR. Until 2011, the treatment protocol for HCV involved the
use of two drugs, ribavirin and interferon. These medications were taken for six to twelve months
and had severe side effects. Since 2011, four new medications have been approved for the treatment
of HCV infection and there are a number of additional medications in the approval process.10 The
new medications for HCV have two main benefits: higher rates of SVR and fewer side effects. The
availability of these medicines has led to increased interest in treating more people for HCV.
Previous models of HCV treatment in the United States have shown that treating HCV infection
reduces morbidity and mortality from HCV.48,49 In addition, there are a number of modeling studies
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that suggest treatment of HCV infection in those who inject drugs could reduce the transmission
of HCV.50–54,83 Mathematical models have also been used to examine the cost effectiveness of the
newer drugs. The first two new drugs approved in the United States, Telaprevir and Boceprevir,
were both found to be cost effective in treating those with evidence of liver damage from HCV.56
Public health agencies such as CDC and state health departments have focused their limitedHCV-
related resources on determining the burden of disease in the United States from HCV infection and
preventing new HCV infections through education and provision of clean injection-drug equipment.
Referral to care and financial assistance for treatments for HCV infection have been limited mostly
to those who are co-infected with HIV. With the introduction of new treatments for HCV infection,
there is growing interest to provide programs designed to link those with HCV infecyion to care.
The programs would aim to get patients into treatment both for the benefit of the individual and
potentially to prevent transmission to others by reducing the reservoir of HCV in the community. It
is not known, however, how best to focus limited resources when linking patients to care. In this
paper we will consider the potential for treating those in the highest burden population for HCV
infection in the United States, those born between 1945 and 1965, and compare the outcomes of
treating persons who inject drugs (PWID) with the outcomes of treating those who don’t inject drugs
(non-PWID).
4.2 Methods
We constructed a state-transition model to represent disease progression and transmission of HCV
to evaluate the public health impact of treatment using direct-acting antivirals on mortality from
HCV in the United States in two populations. The model builds on a published model used by
Salomon and colleagues and Liu and colleagues.56,84,85 The state-transition model reflects HCV
infection progression, infection resolution due to treatment, and mortality under a given treatment
policy scenario. We evaluated disease and mortality outcomes over the lifetime of persons living
in the United States aged 45 to 65 years in 2010 (i.e. birth years 1945 to 1965). Using currently
recommended treatment regimens including simeprevir and sofosbuvir, we considered two treatment
policy scenarios, treating PWID and treating non-PWID, and compared these policies to no treatment
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Figure 4.1: State-transition model of hepatitis C progression
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and treatment using only ribavirin and peginterferon alfa for each population.
In the model, persons infected with HCV (existing cases and new infections) move sequentially
through six stages of HCV infection (infection with no evidence of fibrosis to three levels of fibrosis,
then two levels of cirrhosis) and potentially to HCC. A state-transition diagram of themodel is shown
in Figure 4.1. Transitions can take place annually. All disease states are divided into two genotype
subgroups (type 1 and other) to allow for variation in treatment effectiveness by genotype. The
model was run for two populations: PWID and non-PWID. The populations were assumed to be
completely separate and no initiation or cessation of injection drug use was assumed. Since not all
patients are aware of their HCV status, diagnosis with HCV infection was included in the model for
stages eligible for treatment. The likelihood of being aware of diagnosis with HCV infection was
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considered to be the same across disease states due to screening recommendations in this population
for screening of asymptomatic individuals.
Current guidelines recommend treatment for only some of the HCV-infected persons, those with
severe fibrosis (in this model portal fibrosis with several septa) and those with compensated cirrho-
sis..3,86 Treatment success is modeled as a transition from an infected state to a resolved state and
does not depend on the stage of disease progression. The probability of treatment was assumed to
be the same across the two disease states and the two genotype groups. Persons are eligible for treat-
ment each year they are in a treatment-eligible state (shown in Figure 4.1 as those with a transition to
resolved infection). Persons who are successfully treated move into disease-free states stratified by
the level of liver damage, severe fibrosis, or compensated cirrhosis at the time of treatment. Those
who unsuccessfully complete treatment (i.e., undetectable viral load at six months) remain in the
appropriate disease state, but are no longer eligible for further treatment. Treatment for HCV is de-
pendent on the patient being aware of his or her HCV infection. Persons were assumed to have varied
adherence to the treatment protocol (i.e., did they take all of the doses of medication for the entire
treatment period). For each person receiving treatment, there were two possible adherence levels,
low adherence and high adherence. Treatment success varied depending on adherence. We assumed
that HCC could only occur in those with cirrhosis and that the rate was the same for those with
compensated and decompensated cirrhosis. Only those with the latest stages of disease progression,
decompensated cirrhosis and HCC, are at risk of liver-related death.
We incorporated transmission of HCV to the model as movement from an uninfected state to
HCV infection with no liver damage. The likelihood of infection in this model changes based on
injection drug use and the prevalence of HCV in the PWID population. The probability of infection
(p(Infection)) is modeled as:
p(Infection) = 1  (1  q)N PHCV (4.1)
where q is the probability of infection per injection, N is the number of injections per year, and
PHCV is the prevalence of HCV in the population. HCV prevalence in the population is determined
by using the number of persons in the infected states in the last cycle. The equation for transmission
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Table 4.1: U.S. population estimates for population born between 1945 and 1965
Parameter Population
Percent of total
population born
1945–1965
Total population5 84 169 206 100.00%
Population of PWID23 92 586 0.11 %
Infected with HCV22 75 752 0.09%
Not infected with HCV 16 834 0.02%
Population of non-PWID 84 076 620 99.89%
Infected with HCV4 1 522 996 1.81%
Not infected with HCV 82 553 624 98.08%
Table 4.2: Initial state probabilities conditional on PWID status89
State Initial probabilityfor non-PWID
Initial probability
for PWID
Susceptible 0.981 886 0.225 000
Early infected: Genotype 1 0.006 684 0.284 813
Early infected: Other genotype 0.002 192 0.094 938
Mild fibrosis: Genotype 1 0.004 638 0.197 625
Mild fibrosis: Other genotype 0.001 521 0.065 875
Moderate fibrosis: Genotype 1 0.001 364 0.058 125
Moderate fibrosis: Other genotype 0.000 447 0.019 375
Severe fibrosis: Genotype 1 0.000 682 0.029 063
Severe fibrosis: Other genotype 0.000 224 0.009 688
Compensated cirrhosis: Genotype 1 0.000 103 0.004 377
Compensated cirrhosis: Other genotype 0.000 034 0.001 459
Decompensated cirrhosis 0.000 136 0.005 836
HCC year 156,57,88 0.000 045 0.001 914
HCC year 2 or greater56,57,88 0.000 045 0.001 914
Death from HCV 0 0
Percent with each genotype was assumed to be consistent within each state as disease
progression does not differ across genotypes.
was calibrated to an estimated incidence of 6.6 new cases per 100 person-years for persons over 30
from a prospective cohort study.87 This was used to calibrate Equation 4.1 in the TreeAge model
with no treatment and averaged over the first five years of the model. A pair of parameters was
chosen for use in the model based confidence in the parameter estimates (see Appendix E).
4.2.1 Parameter estimates and data sources
We derived population estimates for the United States from the 2010 U.S. Census (Table 4.1).7
The proportion of the U.S. population infected with HCV was derived separately for persons who
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Table 4.3: Probability of treatment and sustained virologic response
Parameter Baseline Minimum Maximum
SVR probabilities
Probability of SVR in genotype 1 with DAA high 90 63 100
adherence13–23
Probability of SVR in genotype 1 with ribavirin 50 35 69
and peginterferon alfa high adherence94
Probability of SVR in other genotype high adherence13–23 92 90 100
Probability of SVR in genotype 1 with DAA low adherence95 25 0 50
Probability of SVR in genotype 1 with 14 0 28
ribavirin and peginterferon low adherence94
Probability of SVR in other genotype low adherence95 25 0 50
Treatment probability
Probability of treatment per year 25 0 50
Probability of death from treatment56,57 0.5 0.05 1.1
Chance of high adherence56,57 70 50 80
inject drugs and the general population.6,90 The proportion of the population who injects drugs was
taken from the estimate for those over 50 from the National Survey on Drug Use and Health.91
The distributions of the starting non-PWID population and PWID population among the different
health states is shown in Table 4.2, based on a study of the progression of HCV in those infected
by a contaminated blood product over a two year period.89 The proportion of those infected by
genotype 1 (75.3%) was derived from U.S. general population estimates from NHANES estimates
and is incorporated into the estimates shown in Table 4.2.25 The probability of awareness of HCV
diagnosis for the first year was 50% and was taken from literature estimates of the proportion of
those infected that are aware of their infection.48,92,93 Diagnosis in subsequent years was 1% per year
for the base case. The probability of treatment is based on estimates from Liu et al. (Table 4.3).56
Transition probabilities between disease states are taken from previous models when possi-
ble (Table 4.4).56,84,85 Estimates for treatment success were taken from the clinical trials for each
drug.13–20,22,23 Mortality estimates for HCV-related deaths, HCC-related deaths, and mortality from
other causes were taken from CDCWonder and the 2008 U.S. Life Tables. Deaths from HCV infec-
tion, excess deaths in those with HCV infection, and excess deaths in those with injection drug use
were removed from the all-cause mortality estimates.96,97 All-cause mortality estimates for those
with HCV infection and PWID were considered to be higher than for those without HCV infection
and with no injection drug use (Table 4.6). Parameter estimates for transmission of HCV were taken
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Table 4.4: Transition probabilities between HCV disease states
Parameter Base caseestimate Minimum Maximum
Proportion of early infected who never progress 0.24 0.20 0.33
Early infected to mild fibrosis Varies by age; see Table 4.5
Mild fibrosis to moderate fibrosis Varies by age; see Table 4.5
Moderate fibrosis to severe fibrosis Varies by age; see Table 4.5
Severe fibrosis to compensated cirrhosis Varies by age; see Table 4.5
Compensated cirrhosis to decompensated cirrhosis 0.044 0.03 0.06
Decompensated cirrhosis to dead for HCV 0.182 0.065 0.4
Compensated cirrhosis to HCC 0.02 0.015 0.03
Decompensated cirrhosis to HCC 0.02 0.015 0.03
Compensated cirrhosis to resolved See Table 4.3
Severe fibrosis to resolved See Table 4.3
HCC year 1 to death from HCC 0.75 0.3 0.8
HCC year 2 and beyond to death from HCC 0.25 0.1 0.5
Progression variables from previous models.56,57,84,85
Table 4.5: Fibrosis progression by age56,57
Age Probability of progression Minimum Maximum
40–49 0.043 0.03 0.05
50–59 0.099 0.06 0.12
60–69 0.168 0.11 0.2
70–79 0.214 0.14 0.26
80+ 0.232 0.2 0.26
from the substance-abuse literature (Table 4.7).98,99
4.2.2 Analysis
Outcomes for the analysis included number of cases of HCC, deaths from liver-related causes in
those with HCV infection, and number of remaining life-years accrued by the population. One-way
sensitivity analyses were performed on all variables (Appendix B). The model was constructed in
TreeAge Pro, Williamstown, MA: TreeAge Software, 2013. A cycle length of one year was cho-
sen because of the slow progression of HCV infection, the duration of treatment (generally 24 to 48
Table 4.6: Multiplier for increased mortality for those with HCV and persons who inject drugs
Parameter Estimate
HCV infected 3.1 (1.76–5.53)100
Person who injects drugs 11.3 (3.6–27.1)101
49
Table 4.7: Parameter estimates for infection
Parameter Base caseestimate Min Max
Number of needles per month98 15 0 67
Number of needles per year 185 2 798
Number of needles shared99
Often sharers 46.14 0.6 199.5
Sometimes sharers 23.07 0.3 99.75
Never sharers 0 0 0
Percent of injectors in each group
Often sharers 0.39
Sometimes sharers 0.20
Never sharers 0.41
Weighed mean of number shared per year 23 0 98
Probability of infection per infected needle 1.2 0.3 3
weeks), and the duration of acute infection (less than 6 months). Three treatment scenarios were con-
sidered: no treatment, treatment using ribavirin and peginterferon alfa, and treatment using DAAs.
For the treatment scenarios, each HCV-infected person with either severe fibrosis or compensated
cirrhosis had an annual probability of treatment of 0.25. Those who failed treatment were not eligi-
ble for treatment again. The treatment probabilities and outcomes were assumed to be the same for
the PWID and non-PWID groups.
For each scenario, the model was run over a 10-year time horizon, from 2010 to 2020. A 10-year
time period was identified as the timeframe for which current treatment guidelines might be relevant.
The remaining life expectancy of those alive at the end of the time horizon was estimated using the
model with disease progression and state-specific mortality rates without further initiation of HCV
treatment. This allowed us to capture the long-term survival benefits of HCV treatment. Because
of the slow progression of HCV, the benefits of treatment may take years to realize; only including
outcomes in the first 10 years would likely underestimate the benefits of HCV treatments.
4.3 Results
The model of disease progression and transmission showed a reduction in the number of deaths
for HCV-infected persons for both PWID and non-PWID with treatment using DAAs compared to
no treatment or treatment with ribavirin and peginterferon alfa (Table 4.8). The number of cases
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Table 4.8: Results
No treatment Ribavirin and interferon Direct-acting antivirals
Deaths from HCC
PWID 734 693 673
Non-PWID 96 89 85
Deaths from HCV-related cirrhosis
PWID 795 727 693
Non-PWID 116 102 97
treated in the non-PWID cohort was approximately thirty times the number treated in the PWID
cohort when treating the same proportion of cases per year. For the PWID cohort, there were 693
deaths per 100 000 population from HCV-related cirrhosis under DAA treatment compared to 727
per 100 000 population from HCV using ribavirin and peginterferon alfa and 795 deaths per 100 000
population under no treatment. For the entire non-PWID cohort, there were 97 deaths per 100 000
population from HCV-related cirrhosis under DAA treatment, 102 deaths per 100 000 population
from HCV-related cirrhosis under ribavirin and peginterferon alfa treatment, and 116 per 100 000
population under no treatment. Deaths from HCC were counted separately and were also reduced
under treatment. For the PWID cohort, the number of HCC-related deaths was 673 per 100 000
under DAA treatment, 693 per 100 000 under ribavirin and peginterferon alfa treatment, and 734
per 100 000 population under no treatment. For the non-PWID cohort the number of HCC-related
deaths under DAA treatment was 85 per 100 000,under ribavirin and peginterferon alfa treatment
was 89 per 100 000, and under no treatment were 96 per 100 000.
As expected based on the reduction of number of deaths fromHCV and HCC, the predicted num-
ber of life years remaining for a 55-year-old in 2010 from the model was higher under treatment. For
the PWID cohort, the number of life years remaining was 7.37 under DAA treatment, 7.37 under
ribavirin and peginterferon alfa treatment, and 7.36 under no treatment. For the non-PWID cohort,
the number of life years remaining was 27.32 under DAA treatment, 27.31 under ribavirin and pegin-
terferon alfa treatment, and 27.31 under no treatment. These numbers were calculated for the entire
U.S. population born between 1945 and 1965 with only 1.8% infected with HCV. When only those
with HCV infection were included in the non-PWID model, the difference between treatment and
no treatment was much greater (22.16 for DAA versus 22.00 for ribavirin and peginterferon alfa and
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21.27 for no treatment).
New infections only occurred through injection drug use, so the number of new infections could
only be calculated for the PWID cohort. The average annual probability of infection was highest
under no treatment and lowest with DAAs. Under DAA treatment there were 7189 new infections
compared to 7227 with ribavirin and peginterferon alfa and 7304 under no treatment in the first 10
years. This is a difference of 115 cases in DAA treatment versus no treatment in the PWID cohort
born between 1945 and 1965 in the first 10 years.
One-way sensitivity analyses were performed on the probability of resolving each genotype,
treatment probability, diagnosis probability, risk of HCC, and mortality from hepatitis and HCC.
Two sensitivity analyses were performed for probability of resolving genotype 1 and other genotypes
and treatment probability and diagnosis probability (Appendix I). While the number of years of life
remaining changed when these parameters varied, the number of life years remaining with treatment
was always greater than or equal to no treatment. Additional sensitivity analyses were performed
to examine variables that might be targets of policy interventions. These included adherence to
different treatment protocols (Appendix K), screening versus treatment (Appendix J), and inputs for
the transmission equation (Appendix L).
4.4 Discussion
New HCV drugs shown to improve SVR rates for patients with genotype 1, shorten treatment dura-
tion, and reduce side effects were licensed in 2011 and 2013, and it is expected that additional HCV
drugs will be licensed in 2014. All of these medications have been shown to be effective in main-
taining or increasing rates of SVR for HCV and achieving SVR has been demonstrated to reduce
mortality from all causes in persons with HCV.13–23,102 Previously described models have demon-
strated that new HCV treatments are cost effective in treating patients with HCV-related fibrosis
and compensated cirrhosis.53,56,57 Previous modeling studies showed that treating patients for HCV
could prevent transmission of HCV in certain populations.49–55,83 The results of our analysis show
that treatment for HCV infection with currently available drug regimens including simeprevir and
sofosbuvir decreases deaths fromHCV infection, reduces the number of cases of HCC, and increases
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the number of life years remaining for persons aged 45 to 65 years for PWID. These reductions are
greater than those seen with ribavirin and peginterferon alfa alone.
Decreases in deaths from HCV resulted from halting progression of the natural history of in-
fection before moving into states with a risk of death from cirrhosis. The decrease in HCC cases
was the result of preventing progression to cirrhosis in those with severe fibrosis. The decrease in
HCC deaths reflected decreasing HCC incidence. For cases successfully treated for HCV infection,
mortality from other causes may also be reduced leading to increased life expectancy in those with
resolved infection. If HCV treatment does not result in the halting of disease progression, either
because of existing liver damage, co-morbidities, or other factors, the benefit will be reduced.
The proportion of patients treated for HCV was assumed to be 0.25 of those eligible per year.
This proportion was challenging to estimate given the ongoing changes in medications available to
treat HCV. Increasing the proportion of cases treated each year would reduce the number of deaths
and cases of HCC even further. Treating the same proportion of infected persons in each population
required treatment of over 35 times the number of people in the non-PWID population compared
to the PWID population. This would require significantly more resources to implement. Barriers
to treating patients with HCV include the identification of persons infected, duration of treatment,
side effects of treatment, costs of treatment, and high probability of treatment failure. Current CDC
recommendations for screening the cohort of Americans born between 1945 and 1965 are focused
on reducing the number of cases of HCV in the age range with the highest prevalence of HCV
infection that go unrecognized.6 While the benefit of treatment using DAAs compared to ribavirin
and peginterferon alfa alone was not as great as the benefit of using ribavirin and peginterferon alfa
compared to no treatment, the benefits of DAAs for ease of treatment, especially in protocols with
interferon, go beyond better outcomes. The introduction of DAAs for HCV has led to reductions
in the duration of treatment and increased likelihood of SVR, and it may reduce side effects when
used without interferon. In addition, treatment improvements could lead to increased eligibility for
treatment at earlier stages in the progression of liver disease. Patients in this cohort are also reaching
the age of eligibility forMedicare andmay be eligible for treatment once covered. All of these factors
will likely result in more patients in this cohort being treated and reductions in deaths from HCV,
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Table 4.9: Results of calibration for injection equation, pairs using base-case estimates for one parameter
(Appendix E)
Pair Number ofinjections
Probability of HCV
infection per
shared injection
with HCV+ partner
Cases per 100
Base case 23 0.012 20.9
Base case number of injections per
year
23 0.0037 6.6
Base case probability of infection
per injection
7 0.012 6.6
cases of HCC, and deaths from HCC.
The results from this model support the findings of previous models that showed treatment for
HCV prevents transmission of HCV.49–55,83 The reduction in new cases of HCVwas relatively small
due to the population included in the model. While the cohort born between 1945 and 1965 has a
high burden of infection from HCV, this cohort is not at high risk of acquiring HCV infection. In
the at-risk group for HCV in this model, PWID, only 22.5% were estimated to be susceptible to
HCV infection. This represents only 0.02% of the overall population in the cohort. Prevention of
transmission in this age group is not likely an intended goal for treatment programs in the United
States. Only 28.1% of new HCV infections occurred in those over 40 years of age in 2007.82 The
proportion of persons in this cohort who inject is also relatively small at 0.11%.91 The impact of
treatment on the incidence of HCV in the population would be greater in a population with low
prevalence who are at high risk of HCV infection (e.g., new injection-drug users).
There was a high level of uncertainty in many of the parameters in this model. Sensitivity analy-
ses were used to assess the impact of this uncertainty. The parameters for the transmission equation
were particularly challenging to estimate and changes in these parameters led to moderate differ-
ences in the number of infections. An assumption in this model was that persons within this cohort
only shared injection-drug-use equipment with others in the cohort and that sharing occurred ran-
domly within the cohort. There is likely some sharing of equipment between members of this cohort
and those in other age groups. Reducing the prevalence of HCV in the 1945 to 1965 birth cohort
could result in the prevention of transmission to younger age groups. In order to better understand
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transmission between age groups, more information would be needed on patterns of sharing needles
between persons of different ages. In addition, injection drug use is not the only route of transmis-
sion of HCV. Reducing the prevalence of HCV may reduce the transmission of HCV in this cohort
through other routes (e.g., infection-control breaches or needle-stick injuries). Greater differences
might be seen through these routes as more of the non-PWID population is at risk of infection.
In conclusion, in the context of current treatment protocols and resource limitations, the popula-
tion in this cohort that would benefit most from efforts to link HCV-infected cases to care is PWID.
If this is not feasible, there is still a benefit to linking non-PWID cases to care, especially knowing
that transmission occurs through other routes.
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Chapter 5
Overall discussion
We are currently in a time of rapid changes and great possibility in the hepatitis C epidemic in the
United States. The population with the highest burden of disease is reaching the point where the
progression of their hepatitis C infection may lead to cirrhosis and liver cancer, new drugs have
become available to treat hepatitis C, insurance coverage for testing and treatment of hepatitis C is
increasing, and HCV incidence is increasing in young persons who inject drugs. While the problem
of hepatitis C in the United States has been well described, resources for addressing both the high
burden from existing disease and the ongoing transmission of hepatitis C has been limited. All of
these factors combine to make this an important moment in hepatitis C virus policy. The combined
results of the three analyses contained in this paper add to the body of knowledge available on
hepatitis C virus treatment and hepatitis C virus-related liver cancer.
Chapter 2 describes the differences in risk factors for HCC over time and adds to previous work
indicating that certain risk factors for HCC make up an increasing proportion of the HCC cases
over time and that fewer HCC cases have no identified risk factor before diagnosis. The association
between certain identified risk factors and earlier diagnosis indicates that risk-based screening or
increased provider awareness of liver cancer risk may be playing a role in HCC diagnosis in those
with an identified risk. The risk factors that were significantly associated with earlier diagnosis,
HCV infection, HBV infection, and cirrhosis, are those for which HCC screening is currently rec-
ommended in at least some cases. Cirrhosis diagnosis occurred after HCC diagnosis in 41% of
HCV cases with cirrhosis documented, demonstrating that cirrhosis may be undiagnosed in many
cases with known HCV. Since recommendations for HCC screening in those with HCV infection
are limited to HCV cases with cirrhosis, many of those who should be screened may not be. Poten-
tial solutions for addressing this gap include increasing evaluation of those with HCV infection for
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cirrhosis or broadening HCC screening recommendations for those with HCV infection to include
those without documented cirrhosis. More evidence is needed to decide which of these strategies
would be preferred.
The number of HCC cases with HCV infection increased over the time examined, indicating
that the burden of HCV-related HCC continues to grow. This information is useful in better under-
standing the burden of disease from HCV infection in the United States. All of the cases of HCC
included in this analysis were born before 1945. As the birth cohort with the highest prevalence of
HCV reaches the age of eligibility for Medicare, this trend will likely continue for at least the next
20 years. Screening HCV infected persons with cirrhosis is another tool for preventing death from
liver cancer. Earlier diagnosis leads to better outcomes from HCC and HCV infected persons in the
baby boomer population are a prime target for screening programs. As the population of persons
with HCV continues to age, they will likely make up a greater proportion of HCC cases. Outcomes
from HCC could be improved through earlier detection of HCC at a point where treatment may be
possible.
In Chapter 3, the association between HCV diagnosis and 5-year mortality in those with HCC
was examined. Overall, persons with HCV infection and HCC had better 5-year survival than those
without HCV infection even when adjusted by stage, age, and treatment. When stratified by stage
at diagnosis, this association was only present in those diagnosed with a stage of regional. This
may indicate differences in other liver-health-related factors used for staging liver cancer that are
not captured. Those with hepatitis C may have less severe liver disease or comorbidities, increasing
eligibility for treatment. This relationship could also indicate an important difference in liver cancer
outcomes in persons with HCV infection and indicates that those with HCV infection should not be
assumed to be the same as others with liver cancer. Further examination into this relationship would
require detailed information to better determine cancer stage and liver health. This would appear to
be a worthwhile endeavor based on the results in this analysis.
Chapter 4 examines the impact of current treatment of HCV in a population with high burden of
HCV infection in the United States. As the standard protocols for treating hepatitis C virus become
shorter, easier, and more effective the impact of treatment on outcomes and transmission of hepatitis
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could be quite dramatic. Those born between 1945 and 1965 have the highest prevalence of HCV
infection of any birth cohort. There are currently efforts underway to screen every person born
during this time period for HCV infection once and to link those who are infected into care for
their HCV infection. This is a huge undertaking and likely won’t be accomplished completely in
the near future. Public health efforts to assist in linking HCV infected persons to care need to be
focused on the population where the impact would be the greatest. Based on the findings in Chapter 4
and previous work, it appears treating persons who inject drugs would have the most impact. This
policy would prevent more deaths, prevent more cases of liver cancer, and prevent transmission of
HCV through the most common route. This could be accomplished by treating a smaller number
of people in this group than by treating the non-injecting population. Treating persons with HCV
infection who are currently injecting will be challenging and other options may be preferred, but it
appears that focusing on persons who inject drugs is worth consideration. Despite these findings,
treating those with the highest burden of disease, those born between 1945 and 1965, may not be the
best strategy for preventing transmission of HCV when compared with younger injection drug users
who might have a lower prevalence of HCV infection and prevent the progression of disease at an
earlier stage of liver damage. Further examination of treating different populations would allow for
better targeting of linkage to care programs
In conclusion, understanding the consequences of hepatitis C virus infection and how to prevent
them is vital to creating public health programs and treatment strategies to address HCV infection
in the United States. By targeting the highest-impact cases for treatment, screening those with HCV
infection and cirrhosis for HCC, and better understanding differences in liver cancer outcomes in
those with HCC, we can prevent morbidity and mortality from HCV infection.
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Appendix A
Data-source details
Four files were used: (1) Patient Entitlement and Diagnosis Summary File (PEDSF), (2) Medicare
Provider Analysis and Review (MedPar), (3) Carrier Claims (NCH), and (4) Outpatient (OP). The
PEDSF file was used to obtain information on cancer diagnosis, cancer treatment, and death data.
All Medicare files were used to obtain diagnosis information for hepatitis C and other liver-cancer
risk factors (e.g., hepatitis B or alcohol abuse). Surgery and radiation therapy data were obtained
through the PEDSF file. Chemotherapy data were obtained from the OP and NCH files using stan-
dard Healthcare Common Procedure Coding System (HCPCS) codes for chemotherapy (i.e., 964xx,
965xx, and Q0083–Q0085).
Table A.1: Sources of variables for Chapter 3
Variable Data source
Gender SEER: PEDSF
Race SEER: PEDSF
Ethnicity SEER: PEDSF
Age SEER: PEDSF
Cancer diagnosis SEER: PEDSF
Cause of death SEER: PEDSF
Date of death SEER: PEDSF
Surgical resection SEER: PEDSF
Radiation therapy SEER: PEDSF
Chemotherapy Medicare: MedPar, OP, NCH
Hepatitis C diagnosis Medicare: MedPar, OP, NCH
Hepatitis B diagnosis Medicare: MedPar, OP, NCH
Comorbidity Medicare: MedPar, OP, NCH
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Appendix B
Codes for other risks and covariates
Hepatitis C is only one of many known risk factors for HCC. A list of risk factors for HCC was
created using information from the previous studies on liver cancer risk and the American Cancer
Society.60,61,103 Risk history was examined for claims in the twelve months preceding liver cancer
diagnosis. The ICD-9 codes for risk factors are shown in Table B.1 and for covariates are shown in
Table B.2. Not all risk factors for HCC were able to be included in the analysis as some risks are
not likely to appear in the claim data.
Table B.1: ICD-9 codes for risk factors
Risk Codes used
Hepatitis C infection 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, V02.62
Hepatitis B infection 070.20-.23, 070.30-.33, 070.42, V02.61
Hemochromatosis 275.01-.03
Alpha1-antitrypsin deficiency 273.4
Porphyria cutanea tarda 277.1
Glycogen storage diseases 271
Wilson disease 275.1
Tyrosinemia 270.2
Aflatoxin exposure 989.7
Alcohol abuse 571.0, 571.1, 571.2, 571.3, 291.X, 305.0X, V11.3
Cirrhosis 571.2, 571.5, 571.6
Tobacco use 305.1, 989.84, E869.4, V15.82
Obesity 278.00, 278.01, 278.03
Diabetes104 Used CCW diabetes algorithm
Table B.2: Covariates
Covariate Field
Birth year Medicare year of birth
Gender Sex
Race/ethnicity Race
Age at diagnosis Age at diagnosis recode
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Appendix C
HCV case-counting limitations
Hepatitis C status was obtained from the claims files from one year before cancer diagnosis from the
three claims files, Medicare Provider Analysis and Review (MedPar), Carrier Claims (NCH), and
Outpatient Claims (OP). The diagnosis had to be listed on one MedPar claim or two OP or NCH
claims on different dates to be counted as a hepatitis C case. The number of cases with only one
report from NCH and OP was 374. This represented 20% of those with one or more report.
One concern with finding cases of hepatitis C in the claims files was misestimating the number
of cases. Underestimation of cases could occur if hepatitis C was not noted on claims either because
it was not diagnosed or because it was not billed. Based on data found in a recent study looking at
risk factors for HCC in the SEER-Medicare data, the number of cases of HCVmay be undercounted
in this analysis (15% vs. 23%).61 That study looked at risk factors for three or more years before
diagnosis, compared to one year for this analysis. When a sensitivity analysis was performed to
include three years of claims before HCC diagnosis, similar rates of HCV were found.
Overcounting of hepatitis C cases could occur if hepatitis C were noted frequently as a rule-out
diagnosis. A sensitivity analysis was performed to determine whether including cases with only one
report of HCV in the outpatient or carrier file would change the results (Table C.1). When these
additional cases were included, 19% of HCC cases had HCV documented in the Medicare claims.
The hazard ratio for hepatits C was 0.87, the same as in the primary analysis (Table 3.4). All other
covariates remained largely the same.
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Table C.1: HCV case counting sensitivity analysis Cox proportional hazard model with covariates for 5-year
all-cause mortality
Predictor HR p-value
HCV infection 0.87 <0.001
Stage at diagnosis <0.001
Localized Reference
Regional 1.60
Distant 2.52
Unstaged 1.59
Race <0.001
White Reference
Black 1.15
Other 0.87
Asian 0.78
Hispanic 0.96
American Indian 1.11
Unknown 0.97
HBV infection 0.71 <0.001
Male 1.00 0.948
Age at diagnosis <0.001
65–69 Reference
70–74 1.09
75–79 1.16
80–85 1.22
85+ 1.41
Receipt of one or more treatment 0.41 <0.001
Diabetes 1.07 0.001
Cirrhosis 1.08 0.003
Year diagnosed 0.97 <0.001
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Appendix D
State transition model
A few changes to the model used by Salomon and colleagues and modified by Liu and colleagues
were made for this analysis. The liver-transplant state was eliminated, as it was not considered to
be relevant to this analysis. In the analysis by Liu and colleagues, patients could be treated in all
stages of HCV infection. In this analysis, only those with severe fibrosis and compensated cirrhosis
were eligible for treatment based on current recommendations. Race- and gender-specific estimates
were not used. Genotype-specific estimates were added because of the variation in treatment recom-
mendations and outcomes across genotypes. Evaluation of treatment effectiveness was outside the
scope of this analysis, so estimates of treatment success were taken from clinical trial data.
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Appendix E
Validation and calibration
E.1 Calibration of risk of transmission
The equation for transmission was calibrated to an estimated incidence of 6.6 new cases per 100
person-years for persons over 30 from a prospective cohort study.87 This was used to calibrate Equa-
tion 4.1 in the TreeAge model with no treatment and averaged over the first five years of the model.
After identifying plausible ranges for the parameters from the literature, I determined that the base-
line estimates for the parameters produced a much higher than expected rate of HCV incidence in the
population. To identify the best combination of parameter estimates, I performed a two-dimensional
grid search of the parameter space and found the parameter pairs that minimized the mean squared
error between the 5-year average incidence predicted by the model and the literature incidence esti-
mate. Figure E.1 shows a sample of these combinations. There were two estimates that resulted in
Figure E.1: Combinations of parameter estimates
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an estimated incidence of 6.6 per 100 person-years when added to the model using one of the two
baseline estimates from the literature (Table 4.7). The pair with the base case estimate for probability
of infection per injection was used due to a higher confidence in that parameter.
The estimates obtained from the model did not vary greatly based on the parameter pair chosen,
but the implications for policy would certainly vary depending on differences in these parameters.
With a higher likelihood of transmission per injection, reducing transmission of HCVwould bemuch
harder as a single shared needle would represent a high risk of HCV infection. If the likelihood of
transmission per injection is lower, policies providing clean syringes to PWID will have a greater
impact even if the number of shared needles cannot be reduced to zero.
E.2 Validation of natural history of hepatitis C
The natural history portion of the model was calibrated to the models by Liu et al. and Salomon,
Weinstein, Hammitt, and Goldie56,84,85 Altering the model to match the starting age, 40, used by
Salomon and Liu, the estimates obtained were similar. The estimated cumulative probability of
progressing to cirrhosis in this model was 21%. In order to compare this estimate to Salomon and
Liu, the gender-specific estimates were combined into a weighted average overall estimate. For
Salomon the weighted average was 22% (CI 9,40) and for Liu the weighted average was 19%.
The initial probabilities were obtained from the literature and then calibrated using the natural
history model. The model was run for persons aged 25 in 1980 and was run for the period 1980
through 2010. Infection was assumed to take place at the rates estimated by CDC using national
surveillance data.6,105 The estimates from this model were similar to those used in the base-case
estimate. The base case initial probability of being uninfected was 98.1% and the estimate from the
model was 98.5%. Estimates taken from the model were within the range of the estimates used in
sensitivity analyses.
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Appendix F
Sensitivity analysis using AJCC stage
American Joint Committee on Cancer (AJCC) stage was unavailable for cases diagnosed before
2004 (33% of cases in this analysis). AJCC stage was compared to SEER historic stage to confirm
that they were consistent for cases with both stages available. Table F.1 shows this comparison. In
addition, a separate Cox proportional hazard analysis was done for cases with an AJCC stage. The
results of this analysis are shown in Table F.2. The hazard ratio for hepatits C infection is 0.88
compared to 0.87 in the primary analysis. Stage at diagnosis remains significant in this model, but
the trend in AJCC stage is not as clear as when using historic stage. The rest of the covariates remain
largely the same.
Table F.1: Cancer stage consistency
Localized Regional Distant Unstaged
Stage I 1925 89 0 0
Stage II 594 289 0 0
Stage III NOS 11 68 5 0
Stage IIIA 242 623 0 0
Stage IIIB 0 73 40 0
Stage IIIC 0 168 3 0
Stage IV 0 0 959 0
Not applicable 0 0 0 2
Stage unknown 412 330 10 721
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Table F.2: AJCC stage sensitivity analysis Cox proportional hazard model with covariates for 5-year all-cause
mortality
Predictor HR p-value
HCV infection 0.88 <0.001
Stage at diagnosis <0.001
Stage I Reference
Stage II 1.08
Stage III NOS 2.44
Stage IIIA 1.69
Stage IIIB 2.06
Stage IIIC 1.71
Stage IV 2.91
Stage Unknown 1.77
Race <0.001
White Reference
Black 1.17
Other 0.88
Asian 0.78
Hispanic 0.97
American Indian 1.13
Unknown 0.74
HBV infection 0.68 <0.001
Male 0.99 0.677
Age at diagnosis <0.001
65–69 Reference
70–74 1.09
75–79 1.16
80–85 1.18
85+ 1.41
Receipt of one or more treatment 0.43 <0.001
Diabetes 1.06 0.028
Cirrhosis 1.11 0.002
Year diagnosed 0.97 <0.001
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Appendix G
Cirrhosis sensitivity analysis
The proportion of cases of HCV with cirrhosis documented before HCC diagnosis was smaller than
expected. To better describe HCV and cirrhosis in this population, a separate analysis was done
using cirrhosis diagnosis both in the 12 months before HCC diagnosis and after HCC diagnosis. It
is unlikely that cirrhosis occurred after HCC diagnosis, but this may have occurred in some cases.
Those without a diagnosis of cirrhosis before HCC diagnosis would not have been eligible for HCC
screening. If cirrhosis affects outcomes from HCC, the timing of diagnosis would not be relevant.
In the senstivity analysis, the hazard ratio for HCV was 0.92 compared to 0.87 in the primary
analysis, and the hazard ratio for cirrhosis was 0.91 compared to 1.10. It appears that when cirrho-
sis diagnosed before and after HCC diagnosis is included, HCV infection has less of an effect on
mortality, and cirrhosis appears to be protective.
Table G.1: Proportion of hepatitis C cases with cirrhosis documented before and after HCC diagnosis
Not HCV case HCV case
n % n %
Before and after diagnosis
Cirrhosis 4042 48 1261 84
No cirrhosis 4313 52 244 16
Before diagnosis
Cirrhosis 1550 19 744 50
No cirrhosis 6805 81 731 50
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Table G.2: Cirrhosis sensitivity analysis Cox proportional hazard model with covariates for 5-year all-cause
mortality
Predictor HR p-value
HCV infection 0.92 0.006
Stage at diagnosis <0.001
Localized Reference
Regional 1.59
Distant 2.47
Unstaged 1.59
Race <0.001
White Reference
Black 0.96
Other 1.12
Asian 0.86
Hispanic 0.78
American Indian 0.97
Unknown 1.09
HBV infection 0.72 <0.001
Male 1.00 0.948
Age at diagnosis <0.001
65–69 Reference
70–74 1.08
75–79 1.13
80–85 1.17
85+ 1.34
Receipt of one or more
treatment
0.41 <0.001
Diabetes 1.09 <0.001
Cirrhosis 0.91 <0.001
Year diagnosed 0.98 <0.001
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Appendix H
Testing the proportional hazards
assumption for 5-year all-cause
mortality
The test of the proportional hazards assumption was done using time dependent variables for all
covariates. Four were found to be significant: HCV infection, treatment, age at diagnosis, and stage
at diagnosis. When these variables were included in the model for two time periods (i.e., the first 2½
years after diagnosis and the second 2½ years after diagnosis), HCV infection was still associated
with better survival and the hazard ratio was smaller in the corrected model compared to the original
model (0.84 compared to 0.87). The interaction of HCV infection and time was significant, so the
effect of HCV infection on survival is not constant over time. For HCV, the hazard ratio for the first
time period is 0.84, and for the second period is 1.19, so HCV is protective for the first 2½ years
after diagnosis, but not during the second 2½ years. Over the entire 5-year period, those with HCV
are still less likely to die than those without HCV. This makes sense given the shape of the survival
curve stratified by HCV case. The same covariates remain significant in this model.
78
Table H.1: Cox proportional hazard model with covariates for 5-year all-cause mortality, test of the propor-
tional hazards assumption
Predictor HR p-value
HCV infection 0.84 <0.001
Stage at diagnosis <0.001
Localized Reference
Regional 1.60
Distant 2.54
Unstaged 1.62
Race <0.001
White Reference
Black 1.14
Other 0.87
Asian 0.78
Hispanic 0.95
American Indian 1.12
Unknown 0.96
HBV infection 0.71 <0.001
Male 1.00 0.959
Age at diagnosis <0.001
65–69 Reference
70–74 1.08
75–79 1.13
80–85 1.18
85+ 1.36
Receipt of one or more treatment 0.39 <0.001
Diabetes 1.07 <0.001
Cirrhosis 1.08 0.004
Year diagnosed 0.97 <0.001
Interaction of HCV infection and time 1.42 <0.001
Interaction of treatment and time 1.53 <0.001
Interaction of age at diagnosis and time 1.16 <0.001
Interaction of stage and time 0.96 0.024
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Appendix I
Two-way sensitivity analyses
Table I.1: Two-way sensitivity analysis for mortality from HCV and HCC. Additional life years remaining
with treatment
(a) Persons who do not inject drugs
Mortality
from HCV
0.065 0.4
Mortality
from HCC
0.3 0 0
0.8 0 0
(b) Persons who inject drugs
Mortality
from HCV
0.065 0.4
Mortality
from HCC
0.3 0 0.01
0.8 0 0.01
Table I.2: Two-way sensitivity analysis for treatment for genotype 1 and other genotypes. Additional life
years remaining with treatment
(a) Persons who do not inject drugs
Mortality
from HCV
0.63 1
Mortality
from HCC
0.9 0 0
1 0 0
(b) Persons who inject drugs
Mortality
from HCV
0.63 1
Mortality
from HCC
0.9 0.01 0.01
1 0.01 0.01
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Appendix J
Sensitivity analysis for screening versus
treatment to prevent mortality from
HCV infection
Two potential policy strategies could be considered to preventmortality fromHCV infection utilizing
treatment. One would focus on identifying people with HCV infection and the other would focus
on treating persons with HCV infection. With limited resources available, there may be a tradeoff
between the two options. When four potential combinations of testing and treating were examined,
the outcomes varied. In the context of limited resources, a similar comparison could be used to obtain
the preferred strategy. Without costs in the model, choosing parameters for the decrease in treatment
due to an increase in resources being allocated to testing is somewhat arbitrary. This analysis does
demonstrate that the combination of screening and treatment should be considered together when
planning a public health intervention to address hepatitis C.
Table J.1: Sensitivity for screening versus treating with DAAs in persons who inject drugs
Percent diagnosed
per year
Percent treated
per year
Deaths per 100 000
from HCV
0.005 0.30 686
0.010 0.25 693
0.020 0.20 677
0.050 0.10 696
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Appendix K
Sensitivity analysis for adherence to
different treatment protocols
The two treratment protocols for hepatits C examined in this analysis have different side effects,
which may lead to differing adherence. In general, the DAAs will have the same or fewer side ef-
fects compared to ribavirin and peginterferon alfa. A sensitivity analysis was performed to measure
the impact of adherence on mortality from HCV in persons who inject drugs. This analysis showed
that in order to prevent twice as many deaths with DAAs as with ribavirin and peginterferon alfa,
adherence to DAAs would need to be 98%, and adherence to the others would have to be 55%.
An adherence level of 98% is unrealistic in this population, so it is unlikely that the marginal ben-
efit of DAAs compared to ribavirin and peginterferon alfa could equal the benefit of ribavirin and
peginterferon alfa compared to no treatment.
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Table K.1: Impact of treatment with varying adherence to treatments in persons who inject drugs
Adherence Number of deathsfrom HCV
Deaths
prevented
DAA vs. ribavirin and peginterferon alfa
0.70 693 34
0.75 689 38
0.80 683 44
0.90 673 54
0.95 668 59
0.98 665 62
0.99 664 63
Ribavirin and peginterferon alfa vs. no treatment
0.70 727 68
0.65 728 67
0.60 730 65
0.55 733 62
0.50 736 59
0.45 739 56
0.40 741 54
0.35 744 51
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Appendix L
Sensitivity analysis for transmission
equation
A sensitivity analysis was performed to show whether choosing a different combination of parame-
ters for the transmision equation (Equation 4.1) affected the number of deaths from HCV in persons
who inject drugs. No difference was found.
Table L.1: Sensitivity analysis for parameters in the transmission equation
Number of shared
injections (N )
Probability of infection
per injection (q)
Number of deaths
with DAA treatment
Number of deaths
without treatment
7 0.0120 693 795
15 0.0057 693 795
23 0.0037 693 795
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